WO2017085613A1 - Weighing and characterizing materials by acoustic levitation - Google Patents
Weighing and characterizing materials by acoustic levitation Download PDFInfo
- Publication number
- WO2017085613A1 WO2017085613A1 PCT/IB2016/056846 IB2016056846W WO2017085613A1 WO 2017085613 A1 WO2017085613 A1 WO 2017085613A1 IB 2016056846 W IB2016056846 W IB 2016056846W WO 2017085613 A1 WO2017085613 A1 WO 2017085613A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particle
- acoustic
- weight
- agents
- particles
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 254
- 238000005339 levitation Methods 0.000 title claims abstract description 69
- 238000005303 weighing Methods 0.000 title description 20
- 239000002245 particle Substances 0.000 claims abstract description 241
- 238000000034 method Methods 0.000 claims abstract description 116
- 239000007787 solid Substances 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 239000007788 liquid Substances 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 27
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 23
- 230000003287 optical effect Effects 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 239000011343 solid material Substances 0.000 claims description 9
- 230000005684 electric field Effects 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000011344 liquid material Substances 0.000 claims description 6
- 239000002417 nutraceutical Substances 0.000 claims description 6
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 210000003850 cellular structure Anatomy 0.000 claims description 5
- 239000012857 radioactive material Substances 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000000902 placebo Substances 0.000 claims description 4
- 229940068196 placebo Drugs 0.000 claims description 4
- 239000011877 solvent mixture Substances 0.000 claims description 4
- 239000013583 drug formulation Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000000693 micelle Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 230000003313 weakening effect Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 description 35
- 239000002775 capsule Substances 0.000 description 28
- 239000004480 active ingredient Substances 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 239000000047 product Substances 0.000 description 21
- 238000001514 detection method Methods 0.000 description 18
- 230000000699 topical effect Effects 0.000 description 18
- -1 coatings Substances 0.000 description 17
- 230000008569 process Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 229940125681 anticonvulsant agent Drugs 0.000 description 13
- 239000001961 anticonvulsive agent Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 238000003384 imaging method Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000002924 anti-infective effect Effects 0.000 description 11
- 229960005475 antiinfective agent Drugs 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 238000012545 processing Methods 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 239000011324 bead Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 230000005484 gravity Effects 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 239000003708 ampul Substances 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000003416 antiarrhythmic agent Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 229940014259 gelatin Drugs 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000003288 anthiarrhythmic effect Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 239000011162 core material Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000003193 general anesthetic agent Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 229940035674 anesthetics Drugs 0.000 description 4
- 230000003474 anti-emetic effect Effects 0.000 description 4
- 239000002111 antiemetic agent Substances 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000003430 antimalarial agent Substances 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 229940097320 beta blocking agent Drugs 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000193 iodinated contrast media Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 238000011192 particle characterization Methods 0.000 description 4
- 150000002960 penicillins Chemical class 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 239000003451 thiazide diuretic agent Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000674 adrenergic antagonist Substances 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000001078 anti-cholinergic effect Effects 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 229940125683 antiemetic agent Drugs 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940125688 antiparkinson agent Drugs 0.000 description 3
- 239000000939 antiparkinson agent Substances 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- 229940124581 decongestants Drugs 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000003158 myorelaxant agent Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000012634 optical imaging Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N pentadecanoic acid Chemical compound CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229920006328 Styrofoam Polymers 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 230000002682 anti-psoriatic effect Effects 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 229940030999 antipsoriatics Drugs 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 229940121383 antituberculosis agent Drugs 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000002617 bone density conservation agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 239000003576 central nervous system agent Substances 0.000 description 2
- 229940125693 central nervous system agent Drugs 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
- 239000002792 enkephalinase inhibitor Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000002102 nanobead Substances 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940125702 ophthalmic agent Drugs 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 229950000688 phenothiazine Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000008261 styrofoam Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
- 239000000814 tuberculostatic agent Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000000775 AMPA receptor antagonist Chemical class 0.000 description 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 229940124293 CD30 monoclonal antibody Drugs 0.000 description 1
- 229940124294 CD33 monoclonal antibody Drugs 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 1
- 206010058179 Hypertensive emergency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Chemical class 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940124821 NNRTIs Drugs 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 101800001014 Non-structural protein 5A Proteins 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 229940127524 Protease-activated Receptor-1 Antagonists Drugs 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100037346 Substance-P receptor Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229940124304 VEGF/VEGFR inhibitor Drugs 0.000 description 1
- 229940116211 Vasopressin antagonist Drugs 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940126675 alternative medicines Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940124323 amoebicide Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 229940126905 angiotensin receptor-neprilysin inhibitor Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000244 anti-pseudomonal effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 239000000059 antiamebic agent Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124286 antibiotics/antineoplastics Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000003409 antileprotic agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940124289 antineoplastic interferon Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003920 antivertigo agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940097228 centrally acting antiadrenergic agent Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 239000003467 chloride channel stimulating agent Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940075527 detoxifying agent for antineoplastic treatment Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 229940127043 diagnostic radiopharmaceutical Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000001152 differential interference contrast microscopy Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940055061 drug used in alcohol dependence Drugs 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004794 expanded polystyrene Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229940041006 first-generation cephalosporins Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940041010 fourth-generation cephalosporins Drugs 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000028579 gamma-aminobutyric acid uptake involved in synaptic transmission Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000003933 gonadotropin antagonist Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000002607 heparin antagonist Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000011796 hollow space material Substances 0.000 description 1
- 229940124299 hormone/antineoplastic Drugs 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 229940124525 integrase strand transfer inhibitor Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 229940046732 interleukin inhibitors Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical class CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940116557 magnetic resonance imaging contrast media Drugs 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940047091 other immunostimulants in atc Drugs 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 229940125703 otic agent Drugs 0.000 description 1
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940079358 peripheral opioid receptor antagonist Drugs 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 229940097224 peripherally acting antiadrenergic agent Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000002215 photochemotherapeutic effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002379 progesterone receptor modulator Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000012419 revalidation Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000003542 rubefacient Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940041008 second-generation cephalosporins Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 229940046729 selective immunosuppressants Drugs 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940094890 synthetic ovulation stimulants Drugs 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 229940125712 tocolytic agent Drugs 0.000 description 1
- 239000003675 tocolytic agent Substances 0.000 description 1
- 229940026754 topical antivirals Drugs 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960003853 ultrasound contrast media Drugs 0.000 description 1
- 208000030954 urea cycle disease Diseases 0.000 description 1
- 239000002432 uterotonic agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003038 vasopressin antagonist Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
- G01N29/04—Analysing solids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/02—Burettes; Pipettes
- B01L3/0241—Drop counters; Drop formers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
- G01N29/02—Analysing fluids
- G01N29/032—Analysing fluids by measuring attenuation of acoustic waves
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
- G01N29/04—Analysing solids
- G01N29/11—Analysing solids by measuring attenuation of acoustic waves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0626—Fluid handling related problems using levitated droplets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/14—Process control and prevention of errors
- B01L2200/143—Quality control, feedback systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0433—Moving fluids with specific forces or mechanical means specific forces vibrational forces
- B01L2400/0439—Moving fluids with specific forces or mechanical means specific forces vibrational forces ultrasonic vibrations, vibrating piezo elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01G—WEIGHING
- G01G9/00—Methods of, or apparatus for, the determination of weight, not provided for in groups G01G1/00 - G01G7/00
-
- G01N2015/1021—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/023—Solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/024—Mixtures
- G01N2291/02416—Solids in liquids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/024—Mixtures
- G01N2291/02458—Solids in solids, e.g. granules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/024—Mixtures
- G01N2291/02466—Biological material, e.g. blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/028—Material parameters
- G01N2291/02818—Density, viscosity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/028—Material parameters
- G01N2291/02854—Length, thickness
Definitions
- Embodiments of the invention relate to a method or process for determining one or more of weight, mass, shape or other characteristics, of material, especially a material which is in the form of a solid particle or a liquid droplet, and to apparatus and devices designed and configured for that purpose.
- pharmacies hospital and retail
- API active pharmaceutical ingredients
- dosage forms typically oral.
- drug products are developed for the average patient and in one or two or three fixed dosage forms to manage size or gender or age differences.
- the fixed dosage form does not take into account differences in the amount required by individuals due to metabolism, body size or other factors, and this may result in side effects or lack of efficacy.
- the fixed dosages require substantial storage area for the products at a pharmacy or distribution site, and for pharmaceutical companies to spend considerable time and effort to develop formulations containing the API and excipients in a form that can be handled by patients in packaging.
- These formulations are generally designed to enable mass manufacturing of the product by ensuring that a consistent dose of the API is in the product taken by the patient (for example 0 % of the label claim) and that the patient or care provider can handle the product.
- Excipients are added to make the formulation appropriate for processing (for example, API flows in the equipment to dispense a consistent dose in each capsule or tablet or other formulation option) or amenable to handling or compression e.g. into a tablet. This can require costly manufacturing facilities, process, resources and time to produce the finished product.
- Recent genetic and biomarker products enable a specific, or personalized, dose and regime for a specific individual to reduce side effects and improve efficacy.
- Such specific dose(s) is not easily met by the conventional fixed dose formulation approach.
- a personalized dose can be performed manually but is labor intensive, and subject to dispensing errors.
- Problems with such manual formulation include the fact that materials are different and cause issues such as triboelectric interactions, electrostatic repulsion or attraction, the need to account for interparticle cohesive forces which can cause sticking together or to surfaces, or texture inconsistencies resulting in adhesion or repulsion.
- To achieve desired low concentrations it is often required that the compound is dissolved in a solvent and diluted to the desired concentration. This may also lead considerable errors and require the repetition of experiments.
- Such a method and apparatus is particularly suitable and valuable for the preparation and handling of medicinal dosage forms, including without limitation oral, inhalation, intraperitoneally, subcutaneous, intravenous, intramuscular, intraocular and others.
- US 6, 109,098 describes methods and devices for determining the size of particles by sound attenuation and sound speed in liquid matrix.
- US 2012/0197005 provides a method for producing a mixture of amorphous compounds, e.g. from crystalline materials, in an acoustic levitation field without liquid (in the gas phase), comprising supplying a solution containing the compounds; and allowing at least a portion of the solvent of the solution to evaporate while preventing the solute of the solution from contacting a nucleation point.
- US 7080556 describes an ultrasound apparatus and method for the monitoring of melting, mixing and chemical reaction processes.
- WO2000019176 describes an ultrasonic measurement system with molecular weight determination.
- WO201481084 describes a method and apparatus for producing an acoustic field.
- Standing acoustic waves can be relatively powerful and can be used for acoustic levitation, that is, for placing objects or materials in a hovering position without contact to any mechanical device or element. Increasing the power of the acoustic wave will increase the pressure in the standing nodes - eventually becoming high enough to balance the pull of gravity on objects placed in these nodes.
- embodiments of the invention provide apparatus, devices and methods for acoustic levitation as a means to determine, assess, evaluate and/or quantify properties of materials, such as solid particles or liquid droplets Such assessment, evaluation and/or quantification includes, but is not limited to weight and characteristics of the material.
- the property comprises weight.
- the property comprises character of the material, for example: shape, form, density etc.
- Embodiments of the invention comprise apparatus, devices and methods wherein the material property comprises both weight and characteristics.
- Embodiments of the invention provide apparatus, devices and processes to dispense the weighed and/or characterized particles into appropriate containers or devices, making it possible to weigh and deliver exactly controlled amounts of such materials.
- Embodiments of the invention provide apparatus, devices and process for acoustic levitation as a means to weigh, and to characterize, materials comprising solid particles or liquid droplets, and to dispense them into appropriate containers or devices, (for example tableting, capsule, syringe or ampoule filling) wherein the characterization includes (but is not limited to) one or more of determining shape, orientation, form, and density.
- weight is determined by the material's (particle or droplet) position within the levitation field, such as by an optical means or system.
- characteristics of the material may also be determined optically, for example shape and size can be directly assessed.
- optically measured data By applying a calculation to optically measured data, other characteristics can be determined. For example, density may be calculated as is known from a particle's weight and volume.
- the levitation field may be used in in combination with a spectroscopic technique, (for example Raman, infrared or near infrared) and obtained weight or density
- Embodiments of the invention provide apparatus for acoustic levitation comprising one or more acoustic transducers, such as those having an acoustic output in the ultrasonic range, for example greater than 20 kHz, and sound power in the range of 50-180 dBSPL (Decibel sound pressure level).
- the transducer or transducers may produce a sound pressure level in excess of 150 decibels (dBSPL).
- dBSPL decibels
- Embodiments of the present invention allow the processing of materials with morphologies which have poor flow properties and that could normally not or only difficultly be used for drugs in a capsule or other dosage forms or formulations.
- Embodiments of the invention permit measuring the weight of individual particles or of a group of particles and/or determining the number of particles, and/or a distribution of particles.
- the invention comprises an acoustic levitation apparatus and method for determining the weight of a material which is in the form of a solid particle or a liquid droplet, comprising introducing said material into an acoustic levitation field, so that it is positioned and maintained in position (at least during weighing) by an acoustic node of a standing wave in the acoustic levitation field, determining the position of the material and using the position information to determine the weight of the material.
- the position is determined about a vertical axis and relative to the force of gravity.
- the invention relates to a method for dispensing a material in the form of a solid particle or a liquid droplet or mixture, comprising introducing said material into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node of a standing wave in the acoustic levitation field, determining information on any one or more features selected from: particle position; particle shape; particle weight; and particle orientation; and using the obtained feature to move, transfer or dispense the material into a further or final destination.
- particle orientation means the alignment of the particle within the levitation field, for example in the case of a rod-like particle, whether it is aligned more vertically or more horizontally.
- Porition generally is used herein to refer to the location of the material within the three-dimensional confines of the acoustic wave, for example a particle's position within the node of a standing wave. Position is sometimes referred to herein in reference to proximity to an optical detection device.
- the invention describes an acoustic levitation apparatus (one or more devices) appropriate or equipped for carrying out said method, the apparatus comprising an acoustic levitation means, or acoustic levitation system, for generating an acoustic standing wave.
- the means, or system, for generating an acoustic standing wave comprises at least one pair of an acoustic transducer and acoustic reflector, or a pair of acoustic transducers - either or both are sometimes referred to herein as an acoustic transducer pair; together with a position sensing means, or device, for determining the position of a material which is in the form of a solid particle or a liquid droplet.
- This apparatus is preferably (e.g. computer) programmed or can be (e.g. computer) programmed to allow to determine the position of the material to be weighed and to use the position information to determine the weight of said material.
- FIG. 1 shows a schematic representation of an embodiment of an apparatus and system for the acoustic levitation of a material (here represented as a particle).
- Fig. 2 is a plot showing the distribution of sound pressure level (in dB) within an acoustic levitation field versus vertical position (in millimeters from the transducer) within a transducer arrangement according to an embodiment of the invention.
- Fig. 3 is a calibration curve, according to an embodiment of the invention, for a determination of weight of a particle and its vertical position in an acoustic levitation field.
- FIG. 4 schematically represents an apparatus according to an embodiment of the invention that allows for the touch-free transport (dispensing) of a material to a desired destination.
- Fig. 5 schematically illustrates, in an embodiment of the invention, how material levitation is detected and converted to weight measurement.
- Fig 6 illustrates an embodiment of an apparatus and system for the acoustic levitation of a particle, showing an embodiment of both a singulation subsystem and a material transfer and/or dispensing subsystem.
- Fig 7 is a schematic representation of an embodiment of apparatus and method for a material weighing and/or characterizing and dispensing system, wherein multiple particles may be levitated and characterized simultaneously, and shifted or dispensed.
- a system and method for acoustic levitation, wherein the apparatus comprises an acoustic transducer system.
- a transducer configuration designed to acoustically levitate a particle may comprise a single transducer, or may comprise two transducers in parallel, that is, in a spaced-apart, co-axial arrangement, or may comprise a transducer and reflector (also in a spaced-apart axially concentric arrangement).
- the two transducers, or transducer and reflector are oriented vertically.
- the transducers, or transducer and reflector may be oriented at some angle with respect to vertical.
- the transducer pair preferably has an acoustic output in the ultrasonic range, for example, 10 kHz or greater, or 15 kHz or greater, or 20 kHz or greater, or 25 kHz or greater. Use of frequencies below 10 kHz, or even below 1 kHz is feasible, however efficiency may be low and energy requirements are generally higher.
- a node is a point along a standing wave where the wave has minimum amplitude. These occur at equally spaced intervals.
- the opposite of a node is an anti- node, a point where the amplitude of the standing wave is a maximum. These occur midway between the nodes.
- the size such as a geometric diameter, and/or length of the object or material being levitated.
- the material maximum dimension should preferably be less than about one quarter of the wavelength of the sound energy used to levitate; and/or the transducer or transducers must produce enough sound pressure to counteract the pull of gravity on the object or material in order to allow it to hover in the standing wave.
- the method according to embodiments of the invention especially is used for determining the weight where the material (particle or droplet) has a weight in the range from 0.1 ng to 10 g, or from 0.1 ng to 100 mg, or from 1 ng to 50 mg or 5 ng to 10 mg or from 10 ng to 1 mg.
- the method is used where the solid material is a result of precipitating from a liquid material comprising a solution or dispersion, including a suspension of a solid material in a solvent or solvent mixture or an emulsion of a liquid material in a solvent or solvent mixture that is not miscible with the solvent.
- the method according to the previous paragraph further comprises evaporating the solvent and forming the solid material in dry form.
- the dry form may be substantially amorphous, partially amorphous, substantially glassy, partially glassy, substantially crystalline or partially crystalline or a mixture of various solid states.
- the dry form may depend upon the speed of evaporation, which may be supported by supplying energy, e.g. thermal energy, inductive or conductive heating, radiation, infrared, radiofrequency energy for example microwave radiation.
- the material comprises a solid or semisolid, and can be pulverous, crystalline, amorphous, a granule, a particle agglomerate, a mixture of solid states, a viral material, e.g. for vaccination purposes, cell component (e.g.
- membrane vesicles or mitochondria or a cell material (meaning wherever mentioned a material including one or more cells, such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes), and may include dispersed entrapment material (e.g., coatings, nano- and microbeads, micelles, liposomes, nano- and microcapsules, nano- and microspheres).
- Entrapment material may include proteins, lipids, surfactants, polymers, and saccharides.
- solid includes "semisolids,” unless otherwise clear from context.
- Embodiments of the invention are useful in agriculture related chemistry, fine chemistry or other chemistry, and/or the material may comprise a radioactive material or any other material used in small or trace amounts (e.g. antibodies, active proteins, nucleic acids), where exact weighing and distribution of materials is desirable.
- a radioactive material e.g. antibodies, active proteins, nucleic acids
- the material comprises a liquid, such as a droplet.
- the invention relates to a method according to any of the aspects or embodiments described herein, wherein the material comprises a drug, a drug and excipient combination, an excipient, an intermediate for the synthesis of a drug, a cell component, a cellular material, a cell, or a plurality of cells.
- the invention relates to the method according to any of the aspects or embodiments described herein, where the material (e.g. particle or droplet) position is determined by an optical system, especially including any form of an image capture device, such as a camera, or a laser detection system, e.g. a laser interferometer; or by an acoustic system for example one that can detect and measure reflected sound energy e.g. sonar, or radiofrequency system that measures reflected radiofrequency energy e.g. radar.
- an optical system especially including any form of an image capture device, such as a camera, or a laser detection system, e.g. a laser interferometer; or by an acoustic system for example
- Yet another aspect of the invention relates to the method according to any of the aspects or embodiments described herein, comprising further determining the shape of the material, especially where liquid droplet materials are used and more especially where solid materials are involved.
- an acoustic particle levitation method is employed to determine the particle or form (e.g. crystal shape) and/or size in order to permit a conclusion, or decision on a physical or functional attribute of the particle, such as bioavailability and/or processability.
- Such conclusion or decision may be particularly relevant during the manufacture of a pharmaceutical or agrochemicals or cosmetic or other formulation.
- characteristics of the material may be used to sort, or to eliminate, particles having a characteristic which is out of specification.
- a spherical particle having a diameter, size or weight larger than desired may be transferred to a reject container.
- Another aspect of the invention refers to the method according to any of the aspects or embodiments described herein comprising further determining the position and/or orientation of the material.
- a further specific aspect relates to controlling (for example moving modifying or adjusting) either or both of position and orientation of the material (e.g. particle or droplet).
- Another aspect of the invention relates to the method according to any of the invention aspects or embodiments described herein, further comprising determining whether the material is in solid form or in liquid form or a combination or mixture thereof (e.g. a suspension or an emulsion or a micelular form), as well as whether the material is crystalline or amorphous. Aggregates or combinations of the foregoing can also be determined.
- Another aspect of the present invention relates to the method according to any of the aspects or embodiments described herein, wherein multiple particles or droplets are introduced into multiple nodes of the same standing wave simultaneously or sequentially and the determining of the weight of each particle or droplet takes place
- multiple standing waves can be configured or set up in parallel as well, to measure or assess properties of particles or droplets in each standing wave.
- particle introduction may occur in the same step, for example simultaneously or nearly simultaneously as particle formation.
- particles may be created by a particle precipitation process, and the precipitated particles introduced directly into the acoustic levitation system.
- particles may be created by precipitation from a solvent, such as by spray drying, or by precipitation from an anti-solvent.
- the precipitated particles may be subjected to one or more intermediate processes after their introduction into the acoustic levitation system, for example:
- An important aspect of the invention relates to the method according to any aspect or embodiment described herein wherein the material is a drug, an excipient, a drug formulation, or intermediate, or placebo or inactive material.
- the method may comprise determining the weight of a material by a method according to any of the aspects or embodiments of the invention.
- the method further comprises dispensing one or more material particles or droplets into one or more further or final destinations.
- Embodiments of the invention comprise any method described herein wherein the particle or material is transported to a further or final destination which is selected based on information comprising one or more of the features selected from the position, the shape, the weight, or form (e.g. liquid, solid crystalline, amorphous etc.) and/or the orientation of the material, especially one or more of a combination of these features including at least the weight.
- a material may be assessed, determined or evaluated in one or more of the following respects: weight, position, orientation and characteristics (individually and collectively referred to sometimes herein as properties). Such assessment determination or evaluation may arise directly from one or more sensor measurements or inputs, or maybe a combination of sensor measurements, inputs and computed values.
- Embodiments of the present invention further comprise selecting the further or final destination based upon the weight, (for example liquid, solid, amorphous, Crystal polymorphs, solvate, hydrates variations), structure, size and/or shape of the material.
- polymorphic forms may be evaluated for example by assessing packing differences owing to the polymorphic form as measured by density differences and/or in conjunction with some form of imaging, such as spectroscopy.
- the material which is weighed and/or characterized comprises two or more different materials.
- the material may comprise two or more drugs, and/or in the case of a drug formulation one or more excipients with one or more drugs.
- An aspect of the invention relates to any method described herein, wherein the dispensing of the material comprises shifting the position of said material so that it enters a device or container as a further or final destination, especially comprising using a solid particle as material and shifting the position of the material so that it enters a device which is selected from a tableting machine and a capsule filling machine, more especially comprising shifting the position of the material into a container.
- the container may be a capsule, an ampoule, a syringe, a bottle, an infusion container, a sachet, a vial, a spray container or a blister pack, or food product (e.g. nutraceutical) container, each especially for pharmaceutical purposes.
- An aspect of the invention relates to any method described herein, further comprising shifting the material to a destination by using multiple sound transducers, applying electrical fields, using gas (e.g. air) streams or blasts, moving the transducers of the levitating wave and/or superimposing a slow acoustic wave oriented in an angle different from 0 ° relative to a positive pressure node levitating a material (particle or droplet) within the acoustic standing wave, or comprising shifting the material to the destination by weakening or removing the acoustic levitation field, allowing the material to fall (e.g. by gravity) into a destination positioned below the acoustic standing wave, such as below the transducer.
- gas e.g. air
- the method comprising supplying specific amounts or dosages into the device or container by dispensing or shifting the material.
- the material is shifted, moved or affected using a mechanical means or device to transport the material into the device or container.
- the material is shifted, moved or affected acousticly, for example by shifting or moving the position of the transducer pair, and/or by applying a transverse acoustic wave.
- An aspect of the invention relates to any method described herein, comprising determining the vertical position of the material in order to determine the weight of the material. This can be especially important as it allows for precise delivery of amounts of material to containers or ampoules, which may be determined with standard deviations of 1 % or less and thus enables more precision compared to other weight determination methods.
- Another aspect of the invention relates to a method, wherein the position of the material is determined by an optical detection system or by an audio detection system, or both.
- Any method described herein may further comprise measuring the environment in which the levitation takes place, for example within a column of space formed by a pair of transducers, or by a transducer and reflector, in respect of one or more parameters which may comprise temperature, charge (ambient or particle), humidity and pressure.
- appropriate sensors are deployed to detect and/or measure such parameters.
- the results of such sensor measurements provide data which are inputted to an appropriate computing system and may be used as additional or alternative data to control the system, aspects thereof, and/or in calibration, for example by compensating for environmental variables.
- the present invention also, in a further aspect, relates to a device or apparatus appropriate, especially adapted or equipped, e.g. programmed and comprising the means, for executing a method according to any of the invention aspects and
- the invention relates to an apparatus (device) comprising at least one acoustic transducer pair, and at least one position sensing device or means for determining the position of a material which is in the form of a solid particle or a liquid droplet.
- the position sensing device preferably is an optical system, especially comprising a high-speed image capture device, for example a digital imaging system.
- the apparatus for acoustic levitation comprises a material input system, also sometimes referred to as a singulation system or element.
- a material input system may, for example, be a container with the material (which may already be in particle or droplet form, e.g. in the form of a fluid bed (maintained by gas and/or ultrasound) or spouted bed, a microfluidic element allowing to feed droplets of material, a micro cup, a funnel or the like.
- the apparatus further preferably comprises a material transport system or element for shifting the position of the material within an acoustic node to another location, for example a container.
- the material transport system comprises an acoustic aperture.
- a material transport system may be used to refer to either or both of shifting material to a different location, or dispensing.
- the apparatus may, in a further invention embodiment, comprise a material collecting device or means to collect material positioned, characterized and/or weighed in an acoustic node.
- This material collecting means may be a device or a container.
- the material collecting device may be passive, or may be an active device.
- Embodiments of the apparatus and method of the invention can be used in conjunction with generating a material with a certain (e.g. , desired) size and morphology, for example by crystallizing or precipitating from a solvent or anti-solvent.
- material may be crystallized or precipitated in situ within the levitating node, or may be precipitated or crystallized conventionally and fed directly into a bulk dispenser for subsequent singulation.
- This can eliminate conventional processing steps such as milling, and thus may be more efficient with both respect to material and processing time.
- Such an in situ crystallization or precipitation may also eliminate undesirable chemical or pharmacological impurities and/or undesirable solid state polymorphs which can occur during conventional manufacturing, as well as mitigating or eliminating processing and material transportation errors.
- Embodiments of the apparatus and method of the invention afford advantages in manufacturing, for example in fixed dose manufacturing wherein the present invention affords consistency and reliability and can improve homogeniety.
- various dosage strengths may be readily manufactured and without the need for revalidation efforts.
- the use of the present invention in manufacturing also can eliminate the need to mechanically weigh active materials, and in particular when dispensing small doses of highly potent materials, can eliminate requirements for mixing actives with excipients, and consequently heterogenous material errors.
- Embodiments of the system and method of the present invention offer point of care manufacturing capability at a hospital, pharmacy or medical center, thus avoiding high levels of inventory of drug product in distribution sites, packaging process and costs of an analytical testing during and after manufacture, and further can eliminate the need for identity testing after packaging.
- a material may be either solid, semi-solid, or liquid, and in the form of a particle or droplet.
- Particle in particular means a (under the temperature conditions during application of a method or device according to the invention) solid material that may be a monolithic particle or an aggregate of solid material sub-particles, e.g. a granulate or agglomerate.
- the term “particle” may include nanoparticles.
- Droplet in particular means a material with a (under the temperature conditions during application of a method or device according to the invention) liquid continuous matrix which is the sole phase present, or they may comprise solid material (including entrapment material) as non-continuous phase, e.g. as a suspension, or immiscible liquid material, e.g. sub-droplets, e.g. in a water-in-oil or oil-in-water emulsion. Droplets may be disrupted into sub-droplets or they may be united to form larger droplets in the acoustic field or when dispensed into a container or device.
- a "micelle” material is especially one comprising supermolecular colloid particles, often including a packet of chain molecules in parallel arrangement, e.g. formed from surface active (amphiphilic) substances.
- a “liposome” material is especially a material comprising spherical vesicles having at least one lipid bilayer, and may have a single, or multiple concentric or nonconcentric chambers.
- a “nanosphere” or “microsphere” material is especially a hollow material comprising a spherical shell.
- a "nanocapsule” or “microcapsule” material is especially a liquid core material surrounded by a membrane.
- a "nanobead” or “microbead” material is especially a solid core material surrounded by a shell or coating.
- a "viral material” may e.g. be formed from proteins and/or nucleic acids which at least partially correspond to proteins and/or nucleic acids in virus, or genetically modified variants thereof, or complete virus (which may be inactivated e.g. for vaccination purposes).
- a "cell component” may e.g. comprise membrane vesicles from organelle or the outer membrane of cells, or complete organelles, such as mitochondria.
- a "cell material” preferably comprises a material comprising one or more cells, such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes, e.g. cells allowing to provide monoclonal antibodies.
- cells such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes, e.g. cells allowing to provide monoclonal antibodies.
- An “optical system” may be any system, device, component or arrangement which utilizes some form of electromagnetic radiation to detect a physical object.
- Examples of an optical system comprise a camera or a laser detection system.
- a camera system is preferably a high speed camera system.
- a "camera” is an optical instrument allowing recording of images (single images or sequences of images, e.g. in the form of videos or movies) which may be stored, transmitted to another location, or both.
- a digital camera also referred to as a digital imaging system
- the camera may work with the light of the visible spectrum or with other portions of the electromagnetic spectrum, e.g. UV light.
- Suitable imaging protocols include, for example, optical coherence tomography, phase contrast and differential interference contrast microscopy, angle-resolved low-coherence interferometry and phase-contrast X-ray imaging.
- the optical system preferably has a resolution sufficient to be able to adequately image and characterize particles of the size desired, for example those in the 10 to 20 micron size range.
- a magnification of the optical system is preferably around 400 times, or greater.
- a focal length of the system is of a nature such that the lens remains out of the acoustic levitation field.
- a digital imaging system has three components; an image sensor, a lens and body, and software for processing the image.
- the image sensor is a digital integrated circuit that senses light projecting onto the surface of the device. The light is converted into electrical digital pixels. The pixels are arrayed and sent to the software for processing into an image on a computer monitor. Light enters the lens and travels through the body to the digital image sensor.
- Two important parameters of the imaging system are magnification and focal length.
- the magnification is the ability of the lens, image sensor, and software to increase the viewable size of the object.
- the focal length is the distance from the object to the lens.
- a focal length may be at least 50 mm from the lens to the edge of the transducer to prevent interference with the acoustic standing wave.
- the magnification requirement for the levitation system should be sufficient to clearly resolve the smallest size particle being weighed by the apparatus.
- a 20um diameter particle preferably takes a minimum resolution of 100x100 pixels at 100x magnification to produce a 1 ⁇ 2" object on a 10"x10" image on the monitor screen with a 5 megapixel image sensor. This magnification provides sufficient resolution to measure the levitation height of the 20um particle.
- a “laser detection system” is any laser system that allows determining distances or positions of materials, or any other properties thereof, such as its surface properties, refractive index, density or the like. Examples are laser measuring devices or laser interferometers.
- a particle characterization system may be supplied to determine properties and characteristics of a particle for example size, shape, density, surface properties, refractive index, spectral properties (e.g. infrared or raman) and others.
- a particle characterization system may also function as an optical detection system for determining particle position, or may be independent of or in addition to a particle position detection system.
- Laser detection systems can be used both as a particle position detection system and is a particle characterization system.
- Other systems which may be primarily particle characterization includes optical systems which utilize a speckle decorrelation our time of flight algorithm. Such systems allow, for example, so the testing of the kind of surface of a solid or liquid material according to the invention embodiments and make it possible to achieve high precision examination of surface topography.
- Characterization of a particle includes determining shape, size, morphology, surface texture, rugosity density and weight. Such features are properties of a particle may be additionally used to classify, sort, or dispense.
- particles By applying an acoustic wave at any angle to the levitation wave, particles may be rotated, turned or aligned in a particular manner, and ultimately transferred or dispensed based upon such alignment and/or characterization features.
- the standing acoustic levitating wave may be viewed as having an angle of 0° (purely vertical), and the angled acoustic wave may be positioned anywhere between 0 and 180°. Multiple angled waves may be employed to particular benefit.
- the angled wave may sometimes be referred to herein as a wave having a transverse component, or a transverse wave. In some embodiments, the transverse wave is orthogonal to the levitating wave.
- a transverse of wave can rotate a levitated particle, that is, change its orientation, which can assist in obtaining a better image by the optical detection system.
- a transverse wave may be employed to position a particle within a standing node, thus enabling the apparatus to perform an operation on the particle. For example repositioning a particle within the standing node may enable the optical detection system to better focus thereon.
- a transverse wave may be used to manipulate or extract particles having a specific response thereto. For example application of a transverse wave may be used to reposition and thereby deselect or reject particles which are nonuniform or which have a shape which is not desired.
- the term "dispense” or “dispensing” of a material especially relates to its contactless transfer to and deposition at a desired destination.
- the material e.g. particle or droplet
- the material can be delivered in a precise amount and/or with precise characterization knowledge to a desired destination, without the need for the material to contact (or be contacted by) any intermediate surfaces other than those at the destination.
- the term “food product” comprises, for example, a “nutraceutical” (sometimes also called “Functional Food”, “Functional Food product”, “Foodsceutical”, “Medicinal Food” or “Designer Food”) and, according to the present invention embodiments, is defined as food product (including beverages) suitable for human consumption - the expression comprises any fresh or processed food having a health-promoting and/or disease-preventing property beyond the basic nutritional function of supplying nutrients, including food made from functional food ingredients or fortified with health-promoting additives, especially with an effects in the prophylaxis or treatment of one or more of the disorders mentioned herein, in which a material obtained (especially dispensed) according to the invention is added as an ingredient (especially as additive) as health benefit agent, especially in an effective amount, as well as any partially or totally artificially composed food.
- a material obtained (especially dispensed) according to the invention is added as an ingredient (especially as additive) as health benefit agent, especially in an effective amount, as well as any partially or totally artificially composed food.
- nutraceuticals can alternatively be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions, suspensions, parenteral products (e.g. intra venous infusions or injects or subcutaneous injects) or the like.
- composition comprises any type of formulation known in the art.
- Said formulation may comprise one or more drugs ("active ingredients") with or without (pharmaceutically acceptable) excipient(s).
- Drugs comprise, for example, antibodies, antibody fragments, nucleic acids, peptides, vaccines, enzymes, small molecules, organic drugs or other therapeutically active molecules.
- the active ingredient(s) may, for example, comprise (non-limiting) 5-alpha- reductase inhibitors, 5-aminosalicylates, 5HT3 receptor antagonists, AACE inhibitors with calcium channel blocking agents, ACE inhibitors with thiazides, adamantane antivirals, adrenal cortical steroids, adrenal corticosteroid inhibitors, adrenergic bronchodilators, agents for hypertensive emergencies, agents for pulmonary hypertension, aldosterone receptor antagonists, alkylating agents, allergenics, alpha- glucosidase inhibitors, alternative medicines, amebicides, aminoglycosides, aminopeni- cillins, aminosalicylates, AMPA receptor antagonists, amylin analogs, analgesic combinations, analgesics, androgens and anabolic steroids, angiotensin converting enzyme inhibitors, angiotensin II inhibitors with calcium channel blockers, angiotensin I I
- thiazides antiadrenergic agents (peripheral), e.g. with thiazides, antiadrenergic agents, centrally acting antiadrenergic agents, peripherally acting antiandrogens, antianginal agents, antiarrhythmic agents, antiasthmatic combinations, antibiotics/antineoplastics, anticholinergics, antiemetics, anticholinergic antipar- kinson agents, anticholinergic bronchodilators, anticholinergic chronotropic agents, anticholinergics/antispasmodics, anticoagulants, anticonvulsants, antidepressants, antidiabetic agents, antidiabetic combinations, antidiarrheals, antidiuretic hormones, antidotes, antiemetic/antivertigo agents, antifungals, antigonadotropic agents, antigout agents, antihistamines, antihyperlipidemic agents, antihyperlipidemic combinations, antihypertensive combinations, antihyperuricemic agents,
- pylori eradication agents H2 antagonists, hedgehog pathway inhibitors, hematopoietic stem cell mobilizer, heparin antagonists, heparins, HER2 inhibitors, herbal products, histone deacetylase inhibitors, hormones, hormones/antineoplastics, hydantoin anticonvulsants, hydrazide derivatives, illicit (street) drugs, immune globulins, immunologic agents, im- munostimulants, immunosuppressive agents, impotence agents, in vivo diagnostic bio- logicals, incretin mimetics, inhaled anti-infectives, inhaled corticosteroids, inotropic agents, insulininsulin-like growth factor, integrase strand transfer inhibitor, interferons, interleukin inhibitors, interleukins, intravenous nutritional products, iodinated contrast media, ionic iodinated contrast media, iron products, ketolides, laxatives, leprostatics, eukotrien
- Embodiments of the present invention relate to pharmaceutical formulations or compositions that comprise an active ingredient as or included in a material obtained (e.g. dispensed) according to the invention and that can be used especially in the treatment of a disease or condition.
- the material of the present invention may be used, for example, for the preparation of pharmaceutical compositions that comprise a pharmaceutically effective amount of the material.
- the active ingredient in said material may be present in free form or in the form of a pharmaceutically acceptable salt, solvate, hydrate or polymorph, or in admixture with a significant amount of one or more inorganic or organic, solid or liquid,
- compositions for enteral administration such as nasal, buccal, rectal or, especially, oral administration
- parenteral administration such as intravenous, intramuscular or subcutaneous administration, to warm-blooded animals, especially humans
- the compositions comprise the active ingredient alone or, preferably, together with a pharmaceutically acceptable excipient (carrier).
- carrier a pharmaceutically acceptable excipient
- the dosage of the active ingredient depends upon the disease to be treated and upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, and the mode of administration.
- the pharmaceutical compositions may comprise from approximately 0.0001 % to approximately 100% (% referring to weight percent) active ingredient.
- Single-dose administration forms may comprise, in embodiments herein, from approximately 0.001 % to approximately 100% active ingredient and forms that are not of single-dose type may comprise, in embodiments herein, from approximately 5% to approximately 20% active ingredient.
- Unit dose forms are, for example, coated and uncoated tablets, ampoules, vials, suppositories, sachets, sprinkles, spray containers or capsules. Further dosage forms are, for example, ointments, creams, pastes, foams, tinctures, sprays, etc.
- Examples are capsules or tablets or ampoules containing from about 0.0001 mg to about 1 .0 g, e.g. from 0.001 to 5 mg material dispensed according to the invention embodiments.
- compositions of the present invention are, taking reference to the inventive weighing, characterizing, manipulating or dispensing, may otherwise be prepared in a manner as known to the art, for example by means of conventional mixing, granulating, coating, dissolving or lyophilizing processes or by a method or device according to the present invention, or by a combination of conventional preparing and methods of the present invention.
- Embodiments of the present invention comprise solutions of the material with the active ingredient, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example in the case of lyophilized compositions comprising the active ingredient alone or together with a carrier can be made up before use.
- the pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes.
- the said solutions or suspensions may comprise viscosity- increasing agents or solubilizers, such as sodium carboxymethylcellulose, carboxy- methylcellulose, dextran, polyvinylpyrrolidone or gelatin.
- Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes.
- liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to 22, especially from 12 to 22, carbon atoms, for example lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brasidic acid or linoleic acid, if desired with the addition of antioxidants, for example vitamin E, ⁇ -carotene or 3,5-di-tert-butyl-4-hydroxytoluene.
- the alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is a mono- or poly-hydroxy, for example a mono-, di- or tri-hydroxy, alcohol, for example methanol, ethanol, propanol, butanol or pentanol or the isomers thereof, but especially glycol and glycerol.
- fatty acid esters are therefore to be mentioned: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M 2375” (polyoxy- ethylene glycerol trioleate, Gattefosse, Paris), "Miglyol 812” (triglyceride of saturated fatty acids with a chain length of C 8 to C 12 , Huls AG, Germany), but especially vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
- vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
- Injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers.
- the process may be coupled directly to a filling device under sterile conditions such that as a particle is weighed and/or characterized, it may be directly and contactlessly introduced into an ampoule or vial.
- contactless it is meant that no human contact is required and minimal or no machine or surface contact, as once levitated, the particle may be directly transferred to its final destination, such as an ampoule or vial.
- compositions for oral administration which are also especially preferred can be obtained by combining the material with the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragee cores or capsules. It is also possible for them to be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts.
- Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using for example corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, and/or carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. Excipients are especially flow
- conditioners and lubricants for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol.
- Dragee cores are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phtha- late.
- Capsules are dry-filled capsules made of gelatin or HPMC and soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilizers.
- the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added.
- suitable oily excipients such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added.
- Dyes or pigments may be added to the tablets or dragee coatings or the capsule casings, for example for identification purposes or to
- Tablet cores can be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations.
- suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations.
- compositions for oral administration also and especially include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer.
- the hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, binders, and/or glidants, and optionally stabilizers.
- the active ingredient is preferably dissolved or suspended in suitable liquid excipients, to which stabilizers and detergents may also be added.
- compositions suitable for rectal administration are, for example, suppositories that consist of a combination of the active ingredient and a suppository base.
- aqueous solutions of an active ingredient in water- soluble form for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers, are especially suitable.
- the active ingredient optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents.
- Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions.
- the term "excipient” especially refers to any pharmaceutically or nutraceutically acceptable carrier material as already mentioned and also and includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g. , antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art. Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
- a therapeutically effective amount especially refers to an amount of the material obtainable according to the present invention (especially the active ingredient forming it or comprised in it) that will elicit the biological or medical response of a subject suffering from a disease or disease symptoms, including ameliorating the status of a subject suffering from said disease, alleviating the disease or one or more of its symptoms, or preventing the disease, or the like.
- the term “subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g. , humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is in particular a human.
- the dosage of a material obtained (e.g. dispensed) or characterized according to the invention embodiments in pharmaceutical preparations and food products may vary according to the patient's needs, status and condition.
- a daily dosage (which may be split up into two or more, e.g. up to three dosage units) may be in the range from 0.0001 mg to 10,000 mg, such as from 0.001 to 5 mg, e.g. from 0.001 to 1 mg.
- Placebo formulations may comprise solely the excipient material(s) and may be useful in the placebo treatment or in clinical trials.
- Diseases may, for example, comprise infectious and parasitic diseases, especially lower respiratory tract infections, diarrhea, AI DS, tuberculosis, and malaria; neuropsychiatric conditions, e.g. depression; injuries, especially motor vehicle accidents, cardiovascular diseases, heart attacks and stroke, premature birth and other perinatal deaths, gastrointestinal disorders, and cancer. Any disease or disorder is encompassed by these general terms.
- intermediate relates to any compound which is used as starting material or intermediate in the synthesis of a final drug molecule.
- examples are organic low molecular weight compounds, enzymes, antibodies or specifically binding parts thereof, nucleic acids or nucleic acid derivatives, such as siRNA, or the like, especially selected from the active ingredients mentioned above.
- the present invention also comprises the following embodiments, each of which can be claimed:
- a pharmaceutical or neutraceutical composition comprising a material obtained (especially weighed, characterized and/or dispensed) according to a method of the invention as active ingredient together with a pharmaceutically acceptable diluent or carrier, especially for use in the therapeutic and/or prophylactic treatment of a disease or disorder, e.g. mentioned herein.
- a method for the treatment of a disorder comprising administering a pharmaceutically effective amount of a material obtained (especially weighed, characterized and/or dispensed) according to a method of the invention, especially to an individual in need thereof.
- a method as defined above comprising co-administration, e.g. concomitantly or in sequence, a therapeutically effective amount of a material obtained (especially weighed, characterized and/or dispensed) according to a method of the invention, and a different pharmaceutically active compound and/or a pharmaceutically acceptable salt thereof, said different pharmaceutically active compound and/or salt thereof being especially for use in the treatment of any one or more of the disorders set forth herein.
- a combination product comprising a therapeutically effective amount of a material obtained (especially weighed, characterized and/or dispensed) according to a method of the invention, and a different pharmaceutically active compound and/or a
- the invention comprises at least one acoustic transducer pair; together with at least one position sensing means for determining the position of a material which is in the form of a solid particle or a liquid droplet.
- This apparatus is preferably (e.g. computer) programmed or can be (e.g. computer) programmed to allow to determine the position of the material to be weighed and to use the position information to determine the weight of said material.
- FIG. 1 an apparatus 10 illustrating the principle of acoustic levitation is represented.
- a transducer 12 and a reflector 14 are positioned to be coaxial about a center axis AA at a distance that allows an acoustic standing wave to be formed between them.
- a material here in a non-limiting way - a particle 16
- a capture node 18 also sometimes referred to as a positive pressure node, and/or a positive sound pressure zone
- Standing wave 20 is comprised of a direct acoustic wave 20a, and a corresponding reflected acoustic wave 20b.
- Direct and reflected acoustic waves 20a and 20b are essentially superimposed over one another. However solely for clarity in the Figure the two are shown slightly displaced from one another.
- Wave 20 represents the relative amplitude of the sound pressure relative to ambient pressure.
- the portion of wave 20 left of center axis AA represent an acoustic pressure range from positive to ambient and the portion of the wave 20 right of axis AA represent an acoustic pressure range from negative to ambient.
- the capture node 18 is the zone in which particle levitation occurs, and is defined by the region BB as shown in the Figure.
- the capture node 18 is a subset (in this example, the upper half) of a positive pressure zone 24 formed within region CC in the Figure.
- capture node 18 is bounded by a midpoint (viewed along axis AA) of the capture zone 18 and a zero pressure boundary 25 above.
- a zero pressure boundary 25 (also referred to as an anti- node) is found at each point wherein the standing acoustic wave 20 intersects with the center axis AA.
- the particle may drop through this lower part (with declining pressure) and antinode 25 and then be held by the next node 18 in a hovering position or drop e.g. through a hole in the transducer to a desired destination.
- This is one exemplary way to deliver a material without touching (hence contactless) and thus preventing or mitigating contamination or otherwise unwanted surface contact as the particle 16 is delivered to a desired destination.
- contactless dispensing is a benefit for materials which require special containment environments to prevent contamination of material/and or of containment, for example with toxic and or radioactive materials.
- Figure 2 shows an example for the measured sound level for an actually established standing acoustic wave (the sound pressure level profile in the particle levitator for one set of operating conditions actually used).
- a capture node 18 and an antinode 25 of the sound pressure wave 20 and their height relative to a datum (a maximum sound pressure position, i.e. a node) are shown.
- the datum was based upon the top surface of the transducer.
- the sound pressure level can, for example, be determined with a sound pressure calibration sensor (see Figure 4).
- Figure 2 represents measurements of the sound pressure level within the standing acoustic wave.
- the sound pressure amplitude follows a sinusoidal shape which matches the electrical signal used to drive the transducer. Real world effects, including but not limited to, sound harmonics from the transducer, air pressure variation, and ambient noise levels should be considered when calibrating the system to achieve accurate weight measurements.
- Figure 3 depicts a graph of levitation height above a datum versus weight, wherein levitation height corresponds to the particles weight (according to an embodiment of the invention).
- the X axis represents distance from the datum in millimeters and the Y axis is weight in kilograms.
- the particles levitate at different heights depending on their size and hence weight.
- the particles levitate at the height at which acoustic pressure forces are balanced by the force of gravity.
- the "y" equation defines the line and R 2 refers to a statistical measure.
- a calibration curve (represented in Figure 3) is established by actually determining the material's (droplet or particle) position relative to a datum.
- the datum is a predetermined location - for example the surface of the transducer - and can be used for a range of particles with known weights to generate a calibration plot.
- Calibration (and consequent weight determination) may be accomplished using particles or droplets, or combinations thereof.
- weight of a particle is determined by determining the vertical position, that is, a height of the particle relative to a lower sound transducer surface or any other reference height or datum, and comparing the determined height to a calibration plot in order to determine the weight of the particle.
- an audio detection system may comprise a microphone or other sound sensing means as a sensing element, and sound pressure may be measured periodically or continuously.
- sound pressure stability can be used as an internally calibrated method to accurately weigh particles. For example, a target sound pressure may be determined experimentally or by reference to an external standard, and this target sound pressure is maintained via a microphone or sound sensing element coupled to an appropriate internal electronic control system.
- a material is "dispensed" into one or more destinations in accordance with one or more of the methods of the invention, this allows for the delivery of a very precise weight amount to the destination, and/or for the delivery of an otherwise characterized material, as mentioned above and below.
- a destination may be ultimate or final, that is, the end product of the method or process, or intermediate, that is some point before the ultimate or final point in the method or process.
- Such dispensing is useful for materials which require precise weighing a small amounts for example certain biological materials as well as certain highly potent materials.
- Embodiments of the invention provide methods and apparatus for dispensing genetic and biomarker materials and products that enable a specific dose and regimen for a specific individual, and further which can be performed in a highly automated manner.
- Embodiments of the invention also provide consistent product benefits when used with or in novel drug delivery systems which otherwise require a matrix or formulation of very small amounts of material.
- a device or container as final destination may comprise a device that allows for the distribution into a unit form of a pharmaceutical preparation, e.g. a container as mentioned in the following, and may e.g. be an ampoule filling, capsule filling or tablet forming device; a container may e.g. be selected from a capsule, an ampoule, a syringe, a bottle, an infusion container, a sachet, a vial and a blister pack.
- a device or container as further destination may comprise a device or container that is useful or necessary for some further processing, distribution or handling of the material as an intermediate prior to achieving the final unit form of a pharmaceutical preparation, and may e.g. comprise a filling, transporting, or conditioning device; a container may e.g. be selected from a well, capsule, ampoule, syringe, bottle, infusion container, sachet, vial and blister.
- material is shifted to the destination by using multiple sound transducers, which may make use of superimposition of acoustic waves, or a tuning of the waves so that together, at least during the dispensing of a material in liquid droplet or solid particle form, sound waves are influenced and added so as to provide a force that drives the material to or above the desired position.
- This effect may also be obtained by moving the transducers of the levitating wave to a position where the material is to be dispensed.
- superimposing a slow acoustic wave oriented in an angle different from 0° relative to the levitating wave may allow for such shift in the position of the material.
- embodiments of the invention may use gas (e.g. air) streams or blasts, acting upon a material particle or droplet to create a force allowing the material to be dispensed or moved to a desired destination.
- gas e.g. air
- the dispensing method may (in addition or in combination with any one or more of the other methods appropriate, e.g. as just mentioned) comprise shifting the material to the destination by weakening or removing the acoustic levitation field, allowing the material to fall into a desired destination positioned below the material.
- mechanical means may be used to move the material hovering in the levitation field to a desired destination.
- These mechanical means may include directly inserting the destination device or container in the field which may lead to a disruption that allows the hovering material to be supplied to the destination.
- the mechanical means may comprise a manipulator, for example a robot manipulator (e.g. equipped with forceps), plungers, e.g. in rod shape, threads, wires, filaments, sheet-like materials or the like.
- a robot manipulator e.g. equipped with forceps
- plungers e.g. in rod shape, threads, wires, filaments, sheet-like materials or the like.
- the mechanical means used to move shift or dispense the material may comprise a ratchet or conveyor belt, bar or roller that allows to position containers or devices, e.g. vials or ampoules or open capsules or the like, below a position from which the levitation field has been can be adjusted to deliver the material to them, e.g. to a position below the transducer of the apparatus in which acoustic levitation is effected, for example through a hole in said transducer.
- the dispensing takes place without need for the material to come into contact with a surface other than that in or at the destination, thus reducing risks of contamination or material loss on such surfaces.
- a further aspect of the invention relates to any method described herein, comprising providing units of the materials (that is, individual particles or droplets) with an electric charge of identical polarity in order to inhibit its or their aggregation or to move or dispense them by means of electric field(s); or with an electric charge of different polarity in order to promote its or their aggregation or to move or dispense them by means of electric field(s).
- This allows to (e.g. also by moving the material portions towards or away from each other) to form larger particle aggregates or larger droplets.
- Particles may also be moved by applying electrical fields, e.g. using two or more electrodes of appropriate charge.
- Figure 4 shows a schematic representation of an embodiment of the apparatus 10 according to the invention that allows to both measure the material portion, e.g. particle, weight and to dispense the material to a device or container, here to capsule halves 30 on an output device 32, here in the exemplary form of a conveyor or collection device.
- the standing wave 20 (see Figure 1 ) in this example is produced by lower and upper sound transducers 12.
- a particle 16 of material e.g. a particle or droplet of a drug material, such as an ibuprofen particle
- the material introducing means 34 is in communication with an input drop tube 36 which passes through a center of the upper transducer 12.
- the particle 16 travels via the force of gravity to one or more capture nodes 18 (as shown also in Figures 1 and 2).
- the particles 16 may be delivered to a specific capture node 18.
- Arrow 40 represents particle flow in the Figure.
- Capture nodes 18 are represented schematically as ovals with a plus sign (positive pressure).
- Negative pressure zones, or anti-nodes, 25 are represented schematically as ovals with a negative sign.
- one of the capture nodes 18 may function as the weighing node, and one or more other capture nodes 18 may function to characterize the particle 16, and/or to trigger shifting or dispensing of the particle 16.
- a position sensing device or system 42 determines the position of a material portion (e.g. particle 16) at a capture node 18 and thus provides the information required to determine its weight (e.g. from a calibration curve as shown in Figure 3).
- a sound pressure level calibration sensor 44 may be provided e,g, in order to allow for calibration based on sound pressure and/or to control the sound pressure. Control of sound pressure, for example, lowering the sound intensity (energy) or momentarily switching it off entirely, may be used to dispense the particle(s) to a desired destination, such as the capsule halves 30 shown
- the switching of sound energy may be controlled, for example, by appropriate switching elements and processor (not shown).
- the apparatus is configured such that the particle may simply fall through, e.g., an output drop tube 46, disposed, for example within the central aperture of the lower transducer 12 (or reflector) and through which the material portion, e.g. particle 16, may fall without contacting the transducer 12.
- the output may be controlled by an optional output position sensing system (not shown) which may interface with a defective material detection device 49. If employed, the output position sensing system may serve to verify that the weighed and/or characterized particle is dispensed into the appropriate container.
- the defective material detection device 49 may be configured to detect and to divert an out of specification particle. This aspect affords a significant benefit in enabling continuous quality control and continuous manufacturing, for example of drug particles.
- Defective material e.g. of undesired shape, size, weight, form or density
- Defective material may (for example by use of a sound wave applied in a non-vertical, for example orthogonal or perpendicular direction to the standing acoustic wave 20 (represented also by nodes 18 and antinodes 25 in Figure. 4) be dispensed or transferred to a collection vessel 50 under the control of the defective material detection device 49. It is noted that detection device 49 and collection vessel 50 are shown schematically in the figure and thus not intended to be limiting in terms of position or configuration.
- an optional input position sensing system may be positioned near the top of the process flow schematic, for example, near the material introducing means 34, for example, a singulation system. This input position sensing system, in embodiments of the invention, may be used to confirm particle entry.
- the dispensing of material portions may take place laterally (horizontally, e.g. perpendicular to a vertical wave axis) to a position other than the output drop tube 46.
- this may be achieved by applying electrical field (in which case, the material portions are preferably provided in a charged form); or by superimposing a transverse sound wave configured to shift the particles laterally, or combinations thereof.
- Figure 5 shows another schematic representation of the system 10 forming an embodiment of the present invention, for weighing a material particle 16, also schematically depicting the sound pressure wave 20 and showing the particle position relative to a datum 60 which, in this example, is a position of maximum sound pressure in the corresponding capture node 18.
- a datum may be "N" multiples of a wavelength of sound from the top surface of the transducer. "N” may thus be any whole number up to a physical maximum of about fifty.
- An optical position sensing system 42 is shown diagrammatically as a camera, and is used as described herein to determine the position of the material particle 16, here represented as levitating at a height x above the datum 60.
- a computing system 62 allows for determining the weight of the particle 16 and for controlling the system 10.
- devices, apparatus subsystems and means for particle introduction comprise those which achieve particle singulation, that is, in this context, selecting and introducing individual particles, as from a plurality of particles.
- one or more particles may be introduced (or singulated) by one or more mechanical, electrical, or fluidic means or devices.
- a particle may be introduced by means of a vibrating mesh conveyor, or by a screw or auger type feed.
- a fluidized bed particle introducing means, or other microfluidic apparatus or device may serve as the particle introduction means or device.
- particles may be introduced singly and/or multiply by acoustic manipulation, for example weighing performed as a batch process, or particles may be introduced sequentially and acoustic manipulation be performed on a continuous basis, or particles may be introduced in multiples (either single multiples are sequential multiples) and acoustic manipulation performed on the batch of particles, or sequential steps may separate multiple particles into individual manipulators.
- determination of particle characteristics such as weight may occur sequentially, in parallel, or both.
- a device or means for particle singulation that is the introduction of a single particle from a bulk source to enable the determination of particle weight and/or characteristics is useful for the practice of the process of the invention.
- Figure 6 shows an example of a particle singulation subsystem or apparatus. Additionally, Figure 6 shows a more discreet example of a subsystem or apparatus for moving and dispensing particles which have been characterized and/or weighed.
- the basic elements of the apparatus 10 are as shown in Figure 1 and comprise, generally a transducer 12 and reflector 14 and associated control devices.
- a particle singulation system 70 which comprises an embodiment of the particle introduction means 34 (shown schematically in Figure 4).
- Particle singulation system 70 comprises a material input tank 72 which may be fitted with a cap 74 and which feeds a screw or auger feeder 76.
- Screw or auger feeder 76 is driven by a motor 78, in embodiments a stepper motor, and motor 78 is controlled by a controller 80.
- the output of the singulation system 70 is designed to output particles 16 sequentially, and is aligned with the input drop tube 36.
- the particle simulation system 70 may be controlled by a general or specific purpose computer, CPU or processor 81.
- FIG. 6 is also shown position sensing means or unit 42, in this example, comprising an optical imaging device, communicating electrically with the computing system or computer 62. Additionally shown in this figure are details of a drive system for the transducer 12.
- the drive system comprises a power amplifier 84 electrically coupled to the transducer 12.
- a signal generator 86 which may generate a variety of waveforms supplies appropriate waveform information to the power amplifier 84.
- a power supply 88 Also electrically coupled to power amplifier 84.
- the output of signal generator 86 may be controlled by a general or specific purpose computer, CPU or processor 90.
- Figure 6 further illustrates one embodiment of a subsystem and method for moving and/or dispensing into a desired further or final region or container a particle 16 or a plurality of particles 16 which have been weighed and/or characterized.
- an embodiment of the output device 32 holding a plurality of capsules 30 is illustrated.
- the output device 32 and capsules 30 are positioned upon an X-Y gantry 100, which is one known to the art to be configured for an adopted to translate in one or more directions so as to be able to position each individual capsule 30 directly under the output drop tube 46.
- the output device 32 comprises a capsule tray having a plurality of capsule wells 101.
- the position of the gantry 100 with respect to output drop tube 46 may be controlled by a general or specific purpose computer, CPU or processor 104.
- CPU or processor 104 it can be seen that the weighed and/or characterized material comprising particle 16 would fall in the ordinary manner through drop tube 46 but the dispensing location is changed by virtue of the ability to move the gantry 100, to locate each individual well 101 sequentially under the output drop tube 46. Movement of the gantry 100 may be accomplished by any means known to the art such as mechanical, electromagnetic, electrical fluidic etc.
- multiple standing waves can be set up over a single transducer, for example by providing a sound opaque mask, also referred to herein as an acoustic aperture, having a plurality of apertures within which the standing wave is allowed the form, thus generating a number of standing wave columns above a given transducer.
- an acoustic aperture is a structure configured and designed to reduce a size of the sound field generated by the transducer pair and/or to separate the sound field into multiple parallel sound fields within a single transducer pair.
- An acoustic aperture is comprised of a mask of a sound reflecting material including but not limited to glass, plastic, metal, stone, or wood.
- the shape of the mask may be, in embodiments of the invention, congruent with the sound producing surface of the transducer, and may be for example, circular, rectangular, elliptical, or triangular.
- the mask is positioned in close proximity to the transducer (but not in contact) so that sound wave emissions contacting the mask in non-aperture areas are reflected back to the transducer.
- the mask is placed between the transducer and the reflector or two transducers so as to reflect the sound back toward the transducer.
- An aperture is made through the mask to allow the sound wave emanating from the transducer to pass through the mask and move on to the reflector.
- the size and shape of the aperture is designed to reduce the size of the acoustic standing wave and contain particles in a smaller area, and may serve, for example, to ease the depth of field focusing requirements of the digital imaging system.
- the shape of the aperture can be but is not limited to circular, rectangular, elliptical, or triangular.
- the size of the aperture is preferably determined by the size of the particle and by the wavelength of the frequency of sound from the transducer.
- the aperture preferably should be a minimum of three times the particle diameter or 3mm whichever is greater.
- the size of the aperture may be varied with a mechanical iris to provide a highly accurate position of the particle.
- the thickness of the mask is that which is sufficient to mask the sound, and may be as little as 1 mm as long as the sound reflectivity coefficient of the mask is sufficient to reflect most of the sound energy. In embodiments of the invention, it has been found that reflecting about greater than 80% or 90% or 95% provides a practical optimum.
- the maximum thickness of the mask has no theoretical limit and is practically limited by the number of sound wavelengths spacing between the transducer and reflector (i.e. the mask thickness may be equal to one wavelength if the spacing between transducer and reflector is two wavelengths leaving one wavelength above the aperture for inspection and weighing in free space. Multiple apertures may be placed in the mask to allow formation of parallel acoustic standing waves.
- a minimum spacing between apertures is preferably equal to or greater to the aperture size.
- the mask may be mounted such that it can rotate or translate in an X-Y orthogonal manner to move the acoustic standing wave(s) to desired position above the transducer. Motorized mechanisms can be used to provide exact positioning of the acoustic standing wave(s) to present hovering particles before digital imaging systems for weighing and inspection, defect extraction, or the output mechanism. Multiple instruments may be positioned in a radial fashion, subject to instrument spacing requirements, such that the acoustic aperture rotates the acoustic standing wave(s) into positions in front of each instrument for processing.
- FIG. 7 One illustrative embodiment in which this may be accomplished is illustrated, for example, in Figure 7.
- a single particle may be manipulated within each standing wave column, or multiple particles may be manipulated within one or each standing wave column as described.
- Figure 7 illustrates an example embodiment of an apparatus 10 and method for moving and/or dispensing levitated particles comprises a moving (rotating or translating) capture window 112 dispensed above the levitation transducer 12.
- this capture window 112 comprises an "acoustic aperture" to localize the acoustic field to a diameter which is much smaller than that of the acoustic field produced by the transducer.
- the acoustic aperture comprises sound mask, which may be implemented as a rotatable plate 114 with a plurality of apertures 116 (preferably circular) formed therethrough.
- the plate 114 is configured and suspended between the transducer 12 and the reflector 14, such that the apertures 116 are positioned over the transducer so that the sound is reflected by the plate 114 back to the transducer, except in the apertures 116, where sound energy passes through and hits the reflector 14 to form a plurality of standing waves 20.
- At least one particle 20 is stably levitated in each of the aperture 116 regions.
- the aperture size may be determined by the particle size to be manipulated; in embodiments of the invention, these apertures may range in size from about 10 to 30 mm in diameter. Levitated particles can be moved radially by moving the position the apertures 116. In
- the plate 114 (and corresponding apertures 116) may be rotated around a center of the transducer sound field by means of a drive motor 118 mounted upon a support member 120 and mechanically communicating with a gear system 122.
- the acoustic aperture system may be controlled by a general or specific purpose computer, CPU or processor 124.
- Figure 7 depicts the acoustic window as implemented with a rotatable disk
- the acoustic window could comprise a plate comprising a sound mask, which plate is translatable in an XY direction, in addition to or alternatively to being rotatable.
- the plate comprising the sound mask could be offset from a center of transducer 12 such that rotation of the plate could be used to sequentially carry a particle or particles entrained in one of the acoustic standing waves 20 to a location where the particle can be dispensed, for example by further masking the standing wave 20, or simply by moving the plate sufficiently out of range of the sound energy generated by the transducer 12.
- Figures 1 , 6 and 7 illustrate the apparatus in stylized schematic form.
- An implementation of the apparatus could include a housing or enclosed structure for mounting the various components.
- the reflector may include a fine adjustment mechanism (i.e. a threaded rod connecting the reflector to a horizontal brace structure within the housing).
- the calibration microphone may include a mechanical means to position it.
- Other components which could be mounted to the housing may comprise the optical imaging lens, body and sensor; the defect extraction system; the transducer; the material transport system; and the output device(s).
- Other imaging systems may be supplied in mounted within the housing for inspection of particles or droplets.
- within the housing may also be sensors for measuring temperature, humidity, and barometric atmospheric pressure within the housing.
- the location of the sensors would preferably be as close as possible to, but not interfering with, the acoustic sound wave.
- Outputs from one or more of these sensors could be used to control, via the computing system, or via a dedicated control system, elements of the levitation apparatus.
- changes in temperature or pressure may be used to compensate the transducer drive levels to maintain calibrated acoustic sound pressure or to adjust the transducer and reflector spacing to maintain minimal phase differences in the acoustic standing wave.
- All electronic drive components for the input system, microphone, optical imaging, defect extraction, transducer, reflector adjustment, lateral transport, and sensors could be located outside the primary housing in a separate enclosure and may or may not be attached to the housing.
- the external electronic component enclosure may or may not include the computer control system as some embodiments may use a laptop computer and other embodiments may use an embedded host computer in the enclosure.
- the apparatus has been described as controlled by a computing system 62 comprising a computer processor.
- the program environment in which one embodiment of the invention may be executed illustratively incorporates one or more general-purpose computers or special-purpose devices such hand-held computers. Details of such devices (e.g., processor, memory, data storage, input, and output devices) are well known and are omitted for the sake of clarity.
- aspects of methods described herein may be implemented in software running on a computer system, and/or implemented in hardware utilizing one or more processors and logic (hardware and/or software) for performing operations of the method, application specific integrated circuits (ASICs), programmable logic devices such as field programmable gate arrays (FPGAs), and/or various combinations thereof.
- ASICs application specific integrated circuits
- FPGAs field programmable gate arrays
- computing system 62 may be used to control some, a portion, or all elements of the apparatus 10 which require or benefit from computer control.
- one, two, three, or all of the dedicated computers 81 , 90, 104 and 124 may be dispensed with and more than one, or each element of the apparatus 10 controlled by a single computing system 62.
- the examples herein have generally described the apparatus of the present invention in terms of levitating a single particle, the system and method is not so limited. Multiple particles can undergo one or more of the processes of levitation, weighing, characterization and dispensing.
- particles can be moved up and down the column by manipulating sound pressure, for example by decreasing sound pressure to move particles downward towards the transducer, and increasing sound pressure to capture particles again within a capture node.
- a pipeline of particles can be manipulated in this manner, and one or more of the steps comprising levitation, weighing characterizing and dispensing may be performed sequentially or simultaneously.
- column 1 is the diameter of the particles
- column 2 is the levitation height in the positive pressure node
- column 3 is the known weight of the particle
- column 4 is the calculated weight (referred to as Mass Trend) of the particle based on mathematical curve fitting
- column 5 is the absolute error percentage between the known weight and the calculated weight
- column 6 is the calculated weight in milligrams for reference. The average error for this measurement is 5.3%.
- Particles used to obtain the data of Table 1 were 100u particles (Dri-Cal DC-100); 50u particles (ChromoSpheres-T BK050T); and 20u particles (Dri-Cal DC-20); all from Thermo Scientific. While not shown in the table, actual drug particles (comprising ibuprofen) of different sizes, and of higher density than the test particles were successfully levitated as well.
- a Power Amplifier board from Power Amp Design, and a 120V Power supply was used to drive au ultrasonic transducer made by STEM, Inc. cleanly to a full 80 Watts of power.
- Expanded Styrofoam beads of 3mm diameter and weighing approximately 50 milligrams each were levitated. I can levitate multiple beads in a vertical stack. The number of beads is dependent on the number of wavelengths in the space between the transducer and the reflector. Multiple (at least four 4) beads were levitated
- an "acoustic aperture” was made to localize the acoustic field to a relatively small diameter.
- Styrofoam beads (as test particles) were introduced into the circular aperture and were stably levitated, as determined by the absence of visible movement to the naked eye.
- the aperture size may be determined by the particle size to be manipulated.
- a minimum aperture size is 3x the diameter of the particle, for example a 3 mm aperture for a 1 mm particle diameter.
- the bead's position can be altered by moving the position of the aperture around the transducer sound field. The purpose of this feature is to provide positioning of the particle within the apparatus for multiple operations while the particle is held in a relatively constant vertical position by the acoustic standing wave
- the reflector contains a plurality of small apertures designed and configured for dropping beads into the sound field for levitation. Expanded polystyrene test beads were dropped (manually) beads through one of the apertures in the reflector and were captured in an uppermost capture node of the levitation field in ten out of ten attempts.
- This experiment demonstrates that particles can be inputted into the levitation field by dropping them through the reflector.
- the size of the hole and the drop distance to the capture field are important. The size of the hole should be minimized to reduce impact on the acoustic standing wave because a hole allows some portion of the sound pressure to escape rather than be reflected back to the transducer.
- the drop distance is important because the acceleration of the particle due to gravity must be offset by the sound pressure to decelerate the particle to zero velocity and be captured in the capture node.
Abstract
The invention relates to a method of determining the weight of a material which is in the form of a solid particle or a liquid droplet, comprising introducing said material into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node of a standing wave in the acoustic levitation field, determining the position of the material and using the position information to determine the weight of the material; to a method of dispensing a material in the form of a solid particle or a liquid droplet or mixture, comprising introducing said material into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node of a standing wave in the acoustic levitation field, determining information on any one or more features selected from the position, the shape, the weight and the orientation of the material and using the obtained feature to dispense the material into a final destination; and to apparatus for use in the methods mentioned, as well as to related invention aspects.
Description
WEIGHING AND CHARACTERIZING MATERIALS BY ACOUSTIC LEVITATION
SUMMARY OF THE INVENTION
[001] Embodiments of the invention relate to a method or process for determining one or more of weight, mass, shape or other characteristics, of material, especially a material which is in the form of a solid particle or a liquid droplet, and to apparatus and devices designed and configured for that purpose.
BACKGROUND OF THE INVENTION
[002] In many fields of chemical, biological or medical research, for example pharmaceutical research companies often have substantial libraries of compounds or substances that require dispensing prior to testing or preparation. The most desirable way to store each of these compounds is as a solid because doing so reduces the risk of stability issues or precipitation from solutions due to freeze/thawing. Weighing samples manually is often required if the compounds are solids and there are often errors or challenges in dispensing small quantities of highly variable materials with different morphologies (i.e. crystal shapes or amorphous materials or oils, etc). Furthermore only very small quantities may be required to be dispensed (<1 mg) and this is challenging to do accurately or without considerable loss of material or considerable time.
[003] Additionally, pharmacies (hospital and retail) currently provide patients with formulations of active pharmaceutical ingredients (API) as dosage forms, typically oral. Moreover, drug products are developed for the average patient and in one or two or three fixed dosage forms to manage size or gender or age differences. The fixed dosage form does not take into account differences in the amount required by individuals due to metabolism, body size or other factors, and this may result in side effects or lack of efficacy.
[004] The fixed dosages require substantial storage area for the products at a pharmacy or distribution site, and for pharmaceutical companies to spend considerable time and effort to develop formulations containing the API and excipients in a form that can be handled by patients in packaging. These formulations are generally designed to enable mass manufacturing of the product by ensuring that a consistent dose of the API is in the product taken by the patient (for example 0 % of the label claim) and that the patient or care provider can handle the product. Excipients are added to make the
formulation appropriate for processing (for example, API flows in the equipment to dispense a consistent dose in each capsule or tablet or other formulation option) or amenable to handling or compression e.g. into a tablet. This can require costly manufacturing facilities, process, resources and time to produce the finished product.
[005] During the manufacturing of the drug product (i.e. tablet capsule etc.) there may be often issues with homogeneity of the product or stability of the product with excipients or issues with packaging. Extensive time and effort is required to ensure the
manufacturing equipment is clean correctly to avoid cross contamination of drugs and consequent potential harm to patients. Furthermore, customarily two years of shelf life have to be generated on each product so that the product is stable during shipment, storage at the pharmacy and during period with the patient. In addition many patients are on multiple treatments and combination of API's. This makes it difficult for patients to be compliant.
[006] Recent genetic and biomarker products enable a specific, or personalized, dose and regime for a specific individual to reduce side effects and improve efficacy. Such specific dose(s) is not easily met by the conventional fixed dose formulation approach. A personalized dose can be performed manually but is labor intensive, and subject to dispensing errors. Problems with such manual formulation include the fact that materials are different and cause issues such as triboelectric interactions, electrostatic repulsion or attraction, the need to account for interparticle cohesive forces which can cause sticking together or to surfaces, or texture inconsistencies resulting in adhesion or repulsion. Furthermore it is difficult to measure accurately amounts of 5 or less mg, especially < 1 mg, and consequently much material is wasted due to higher than required amounts being used to ensure an accurate weighing. To achieve desired low concentrations it is often required that the compound is dissolved in a solvent and diluted to the desired concentration. This may also lead considerable errors and require the repetition of experiments.
[007] In fields other than pharmaceutical (e.g. agriculture related chemistry, chemistry and fine chemistry), as well as in fields implicating radioactive materials (where the use of contactless methods is especially useful, allowing to characterize and dispense material minimizing loss and minimizing contamination from or between toxic or radioactive materials) or other fields wherein materials are used in trace amounts (e.g. antibodies, active proteins, nucleic acids), methods and apparatus for exact weighing
and distribution, especially contactless weighing and distribution, of materials is desirable.
[008] In view of these issues and limitations of drug or other material handling and dispensing, it is desirable to provide a method and apparatus which afford determination of exact amounts (for example, by weight, by physical size or shape or other
characteristics or combinations thereof) of materials and which allow dispensing them, for example in containers or devices without having to touch them by any mechanical means during weighing and dispensing. Such a method and apparatus is particularly suitable and valuable for the preparation and handling of medicinal dosage forms, including without limitation oral, inhalation, intraperitoneally, subcutaneous, intravenous, intramuscular, intraocular and others.
[009] US 6, 109,098 describes methods and devices for determining the size of particles by sound attenuation and sound speed in liquid matrix.
[0010] US 2012/0197005 provides a method for producing a mixture of amorphous compounds, e.g. from crystalline materials, in an acoustic levitation field without liquid (in the gas phase), comprising supplying a solution containing the compounds; and allowing at least a portion of the solvent of the solution to evaporate while preventing the solute of the solution from contacting a nucleation point.
[0011] US 7080556 describes an ultrasound apparatus and method for the monitoring of melting, mixing and chemical reaction processes.
[0012] WO2000019176 describes an ultrasonic measurement system with molecular weight determination. WO201481084 describes a method and apparatus for producing an acoustic field.
GENERAL DESCRIPTION OF THE INVENTION
[0013] Standing acoustic waves can be relatively powerful and can be used for acoustic levitation, that is, for placing objects or materials in a hovering position without contact to any mechanical device or element. Increasing the power of the acoustic wave will increase the pressure in the standing nodes - eventually becoming high enough to balance the pull of gravity on objects placed in these nodes.
[0014] Accordingly, embodiments of the invention provide apparatus, devices and methods for acoustic levitation as a means to determine, assess, evaluate and/or quantify properties of materials, such as solid particles or liquid droplets Such
assessment, evaluation and/or quantification includes, but is not limited to weight and characteristics of the material. Accordingly, in embodiments of the invention the property comprises weight. In embodiments of the invention, the property comprises character of the material, for example: shape, form, density etc. Embodiments of the invention comprise apparatus, devices and methods wherein the material property comprises both weight and characteristics. Embodiments of the invention provide apparatus, devices and processes to dispense the weighed and/or characterized particles into appropriate containers or devices, making it possible to weigh and deliver exactly controlled amounts of such materials.
[0015] Embodiments of the invention provide apparatus, devices and process for acoustic levitation as a means to weigh, and to characterize, materials comprising solid particles or liquid droplets, and to dispense them into appropriate containers or devices, (for example tableting, capsule, syringe or ampoule filling) wherein the characterization includes (but is not limited to) one or more of determining shape, orientation, form, and density.
[0016] In embodiments of the invention, weight is determined by the material's (particle or droplet) position within the levitation field, such as by an optical means or system. In embodiments of the invention, characteristics of the material may also be determined optically, for example shape and size can be directly assessed. By applying a calculation to optically measured data, other characteristics can be determined. For example, density may be calculated as is known from a particle's weight and volume. In addition, the levitation field may be used in in combination with a spectroscopic technique, (for example Raman, infrared or near infrared) and obtained weight or density
measurements to determine the solid-state form, or particle size, or morphology (i.e. amorphous, hydrate, polymorph, solvate, co-crystal, etc.) of an individual particle or group of particles in order to select and dispense only a a desired particle.
[0017] Embodiments of the invention provide apparatus for acoustic levitation comprising one or more acoustic transducers, such as those having an acoustic output in the ultrasonic range, for example greater than 20 kHz, and sound power in the range of 50-180 dBSPL (Decibel sound pressure level). In embodiments of the invention, the transducer or transducers may produce a sound pressure level in excess of 150 decibels (dBSPL).
[0018] The acoustic levitation apparatus and process of the present invention thus allows one or more of: separation of a particle or particles e.g. of an active
pharmaceutical compound from a bulk reservoir either as individual particles or a group of particles; providing an accurate particle weight; moving, dispensing or transferring the particle or particles to a capsule or other formulation unit; and depositing the particle or particles in a controlled manner. Embodiments of the present invention allow the processing of materials with morphologies which have poor flow properties and that could normally not or only difficultly be used for drugs in a capsule or other dosage forms or formulations. Embodiments of the invention permit measuring the weight of individual particles or of a group of particles and/or determining the number of particles, and/or a distribution of particles.
[0019] In many embodiments, the invention comprises an acoustic levitation apparatus and method for determining the weight of a material which is in the form of a solid particle or a liquid droplet, comprising introducing said material into an acoustic levitation field, so that it is positioned and maintained in position (at least during weighing) by an acoustic node of a standing wave in the acoustic levitation field, determining the position of the material and using the position information to determine the weight of the material. In many embodiments, the position is determined about a vertical axis and relative to the force of gravity.
[0020] In many embodiments, the invention relates to a method for dispensing a material in the form of a solid particle or a liquid droplet or mixture, comprising introducing said material into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node of a standing wave in the acoustic levitation field, determining information on any one or more features selected from: particle position; particle shape; particle weight; and particle orientation; and using the obtained feature to move, transfer or dispense the material into a further or final destination.
[0021] Generally as used herein, particle orientation means the alignment of the particle within the levitation field, for example in the case of a rod-like particle, whether it is aligned more vertically or more horizontally. "Position" generally is used herein to refer to the location of the material within the three-dimensional confines of the acoustic wave, for example a particle's position within the node of a standing wave. Position is sometimes referred to herein in reference to proximity to an optical detection device.
[0022] In many embodiments, the invention describes an acoustic levitation apparatus (one or more devices) appropriate or equipped for carrying out said method, the apparatus comprising an acoustic levitation means, or acoustic levitation system, for generating an acoustic standing wave. In many embodiments the means, or system, for generating an acoustic standing wave comprises at least one pair of an acoustic transducer and acoustic reflector, or a pair of acoustic transducers - either or both are sometimes referred to herein as an acoustic transducer pair; together with a position sensing means, or device, for determining the position of a material which is in the form of a solid particle or a liquid droplet. This apparatus is preferably (e.g. computer) programmed or can be (e.g. computer) programmed to allow to determine the position of the material to be weighed and to use the position information to determine the weight of said material.
DESCRI PTION OF THE DRAWI NGS
[0023] The Figures show exemplary invention embodiments as follow:
[0024] Fig. 1 shows a schematic representation of an embodiment of an apparatus and system for the acoustic levitation of a material (here represented as a particle).
[0025] Fig. 2 is a plot showing the distribution of sound pressure level (in dB) within an acoustic levitation field versus vertical position (in millimeters from the transducer) within a transducer arrangement according to an embodiment of the invention.
[0026] Fig. 3 is a calibration curve, according to an embodiment of the invention, for a determination of weight of a particle and its vertical position in an acoustic levitation field.
[0027] Fig. 4 schematically represents an apparatus according to an embodiment of the invention that allows for the touch-free transport (dispensing) of a material to a desired destination.
[0028] Fig. 5 schematically illustrates, in an embodiment of the invention, how material levitation is detected and converted to weight measurement.
[0029] Fig 6 illustrates an embodiment of an apparatus and system for the acoustic levitation of a particle, showing an embodiment of both a singulation subsystem and a material transfer and/or dispensing subsystem.
[0030] Fig 7 is a schematic representation of an embodiment of apparatus and method for a material weighing and/or characterizing and dispensing system, wherein multiple particles may be levitated and characterized simultaneously, and shifted or dispensed.
DETAI LED DESCRI PTION OF THE I NVENTION
[0031] In embodiments of the invention, there is provided a system (apparatus) and method for acoustic levitation, wherein the apparatus comprises an acoustic transducer system. A transducer configuration designed to acoustically levitate a particle may comprise a single transducer, or may comprise two transducers in parallel, that is, in a spaced-apart, co-axial arrangement, or may comprise a transducer and reflector (also in a spaced-apart axially concentric arrangement). In embodiments of the invention, the two transducers, or transducer and reflector, are oriented vertically. In embodiments of the invention, the transducers, or transducer and reflector, may be oriented at some angle with respect to vertical.
[0032] The transducer pair preferably has an acoustic output in the ultrasonic range, for example, 10 kHz or greater, or 15 kHz or greater, or 20 kHz or greater, or 25 kHz or greater. Use of frequencies below 10 kHz, or even below 1 kHz is feasible, however efficiency may be low and energy requirements are generally higher.
[0033] It is important to tune the correct frequency to match the distances between the transducer or transducers or the reflecting elements and/or vice versa in order to create the desired standing wave with stable nodes and antinodes. For purposes of the present invention, a node is a point along a standing wave where the wave has minimum amplitude. These occur at equally spaced intervals. The opposite of a node is an anti- node, a point where the amplitude of the standing wave is a maximum. These occur midway between the nodes.
[0034] In addition to the frequency and amplitude of the wave, other factors are also important. Such factors include, for example, the size, such as a geometric diameter, and/or length of the object or material being levitated. The material maximum dimension should preferably be less than about one quarter of the wavelength of the sound energy used to levitate; and/or the transducer or transducers must produce enough sound pressure to counteract the pull of gravity on the object or material in order to allow it to hover in the standing wave.
[0035] The method according to embodiments of the invention, especially is used for determining the weight where the material (particle or droplet) has a weight in the range from 0.1 ng to 10 g, or from 0.1 ng to 100 mg, or from 1 ng to 50 mg or 5 ng to 10 mg or from 10 ng to 1 mg.
[0036] In an aspect of the invention, the method is used where the solid material is a result of precipitating from a liquid material comprising a solution or dispersion, including a suspension of a solid material in a solvent or solvent mixture or an emulsion of a liquid material in a solvent or solvent mixture that is not miscible with the solvent.
[0037] In an aspect of the invention, the method according to the previous paragraph further comprises evaporating the solvent and forming the solid material in dry form. The dry form may be substantially amorphous, partially amorphous, substantially glassy, partially glassy, substantially crystalline or partially crystalline or a mixture of various solid states. In embodiments of the invention, the dry form may depend upon the speed of evaporation, which may be supported by supplying energy, e.g. thermal energy, inductive or conductive heating, radiation, infrared, radiofrequency energy for example microwave radiation.
[0038] In embodiments of the invention, the material comprises a solid or semisolid, and can be pulverous, crystalline, amorphous, a granule, a particle agglomerate, a mixture of solid states, a viral material, e.g. for vaccination purposes, cell component (e.g.
membrane vesicles or mitochondria) or a cell material (meaning wherever mentioned a material including one or more cells, such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes), and may include dispersed entrapment material (e.g., coatings, nano- and microbeads, micelles, liposomes, nano- and microcapsules, nano- and microspheres). Entrapment material may include proteins, lipids, surfactants, polymers, and saccharides. As used herein, the term "solid" includes "semisolids," unless otherwise clear from context.
[0039] Embodiments of the invention are useful in agriculture related chemistry, fine chemistry or other chemistry, and/or the material may comprise a radioactive material or any other material used in small or trace amounts (e.g. antibodies, active proteins, nucleic acids), where exact weighing and distribution of materials is desirable.
[0040] In embodiments of the invention the material comprises a liquid, such as a droplet.
[0041] In another aspect of the invention, the invention relates to a method according to any of the aspects or embodiments described herein, wherein the material comprises a drug, a drug and excipient combination, an excipient, an intermediate for the synthesis of a drug, a cell component, a cellular material, a cell, or a plurality of cells.
[0042] In another aspect of the invention, the invention relates to the method according to any of the aspects or embodiments described herein, where the material (e.g. particle or droplet) position is determined by an optical system, especially including any form of an image capture device, such as a camera, or a laser detection system, e.g. a laser interferometer; or by an acoustic system for example one that can detect and measure reflected sound energy e.g. sonar, or radiofrequency system that measures reflected radiofrequency energy e.g. radar.
[0043] Yet another aspect of the invention relates to the method according to any of the aspects or embodiments described herein, comprising further determining the shape of the material, especially where liquid droplet materials are used and more especially where solid materials are involved. In aspects of the invention, an acoustic particle levitation method is employed to determine the particle or form (e.g. crystal shape) and/or size in order to permit a conclusion, or decision on a physical or functional attribute of the particle, such as bioavailability and/or processability. Such conclusion or decision may be particularly relevant during the manufacture of a pharmaceutical or agrochemicals or cosmetic or other formulation.
[0044] In aspects of the invention, characteristics of the material may be used to sort, or to eliminate, particles having a characteristic which is out of specification. For example, a spherical particle having a diameter, size or weight larger than desired may be transferred to a reject container.
[0045] Another aspect of the invention refers to the method according to any of the aspects or embodiments described herein comprising further determining the position and/or orientation of the material. A further specific aspect relates to controlling (for example moving modifying or adjusting) either or both of position and orientation of the material (e.g. particle or droplet).
[0046] Another aspect of the invention relates to the method according to any of the invention aspects or embodiments described herein, further comprising determining whether the material is in solid form or in liquid form or a combination or mixture thereof (e.g. a suspension or an emulsion or a micelular form), as well as whether the material is crystalline or amorphous. Aggregates or combinations of the foregoing can also be determined.
[0047] Another aspect of the present invention relates to the method according to any of the aspects or embodiments described herein, wherein multiple particles or droplets
are introduced into multiple nodes of the same standing wave simultaneously or sequentially and the determining of the weight of each particle or droplet takes place
simultaneously (in parallel) or sequentially. In this aspect, multiple standing waves can be configured or set up in parallel as well, to measure or assess properties of particles or droplets in each standing wave.
[0048] In aspects of the invention, particle introduction may occur in the same step, for example simultaneously or nearly simultaneously as particle formation. For example, particles may be created by a particle precipitation process, and the precipitated particles introduced directly into the acoustic levitation system. In aspects of the invention, particles may be created by precipitation from a solvent, such as by spray drying, or by precipitation from an anti-solvent. In one more embodiments of the invention, the precipitated particles may be subjected to one or more intermediate processes after their introduction into the acoustic levitation system, for example:
inspection for size, shape, color or orientation in the levitation field
[0049] An important aspect of the invention relates to the method according to any aspect or embodiment described herein wherein the material is a drug, an excipient, a drug formulation, or intermediate, or placebo or inactive material. The method may comprise determining the weight of a material by a method according to any of the aspects or embodiments of the invention.
[0050] In embodiments of the method of the invention especially any aspects or embodiments of the method wherein the material is weighed, the method further comprises dispensing one or more material particles or droplets into one or more further or final destinations.
[0051] Embodiments of the invention comprise any method described herein wherein the particle or material is transported to a further or final destination which is selected based on information comprising one or more of the features selected from the position, the shape, the weight, or form (e.g. liquid, solid crystalline, amorphous etc.) and/or the orientation of the material, especially one or more of a combination of these features including at least the weight. It may be noted that as a general (and non-limiting) summary of the capabilities of the acoustic levitation system described herein, that a material may be assessed, determined or evaluated in one or more of the following respects: weight, position, orientation and characteristics (individually and collectively referred to sometimes herein as properties). Such assessment determination or
evaluation may arise directly from one or more sensor measurements or inputs, or maybe a combination of sensor measurements, inputs and computed values.
[0052] Embodiments of the present invention further comprise selecting the further or final destination based upon the weight, (for example liquid, solid, amorphous, Crystal polymorphs, solvate, hydrates variations), structure, size and/or shape of the material. In embodiments of the present invention, polymorphic forms may be evaluated for example by assessing packing differences owing to the polymorphic form as measured by density differences and/or in conjunction with some form of imaging, such as spectroscopy.
[0053] The method according to any aspect or embodiment comprising dispensing more than one material particle or droplet to the same further or final destination and thus accumulating the material at that destination, especially comprising accumulating up to 1 or 2 or 3 or 4 or 5 or 10 g or more of material at the same destination.
[0054] The method according to any aspect or embodiment described herein, wherein the material (particle or droplet) which is weighed and/or characterized comprises two or more different materials. In particular in the case where the material is a drug, the material may comprise two or more drugs, and/or in the case of a drug formulation one or more excipients with one or more drugs.
[0055] An aspect of the invention relates to any method described herein, wherein the dispensing of the material comprises shifting the position of said material so that it enters a device or container as a further or final destination, especially comprising using a solid particle as material and shifting the position of the material so that it enters a device which is selected from a tableting machine and a capsule filling machine, more especially comprising shifting the position of the material into a container. The container may be a capsule, an ampoule, a syringe, a bottle, an infusion container, a sachet, a vial, a spray container or a blister pack, or food product (e.g. nutraceutical) container, each especially for pharmaceutical purposes.
[0056] An aspect of the invention relates to any method described herein, further comprising shifting the material to a destination by using multiple sound transducers, applying electrical fields, using gas (e.g. air) streams or blasts, moving the transducers of the levitating wave and/or superimposing a slow acoustic wave oriented in an angle different from 0 ° relative to a positive pressure node levitating a material (particle or droplet) within the acoustic standing wave, or comprising shifting the material to the destination by weakening or removing the acoustic levitation field, allowing the material
to fall (e.g. by gravity) into a destination positioned below the acoustic standing wave, such as below the transducer.
[0057] The method according to any aspect or embodiment described herein, comprising supplying specific amounts or dosages into the device or container by dispensing or shifting the material. In a further aspect of the invention the material is shifted, moved or affected using a mechanical means or device to transport the material into the device or container. In a further aspect, the material is shifted, moved or affected acousticly, for example by shifting or moving the position of the transducer pair, and/or by applying a transverse acoustic wave.
[0058] The method according to any aspect or embodiment, comprising using mechanical means to move the receiving device and container under the material while it is in the levitating field, and subsequently disabling the levitating field, allowing the particle to fall by gravity into an appropriate container or destination.
[0059] An aspect of the invention relates to any method described herein, comprising determining the vertical position of the material in order to determine the weight of the material. This can be especially important as it allows for precise delivery of amounts of material to containers or ampoules, which may be determined with standard deviations of 1 % or less and thus enables more precision compared to other weight determination methods.
[0060] Another aspect of the invention relates to a method, wherein the position of the material is determined by an optical detection system or by an audio detection system, or both.
[0061] Any method described herein may further comprise measuring the environment in which the levitation takes place, for example within a column of space formed by a pair of transducers, or by a transducer and reflector, in respect of one or more parameters which may comprise temperature, charge (ambient or particle), humidity and pressure. In such embodiment, appropriate sensors are deployed to detect and/or measure such parameters. The results of such sensor measurements provide data which are inputted to an appropriate computing system and may be used as additional or alternative data to control the system, aspects thereof, and/or in calibration, for example by compensating for environmental variables.
[0062] The method according to any one of the aspects or embodiments described herein comprising determining the weight of the material (e. g. particle or droplet) by
calibration with particles or droplets of known weight. For example, this could be accomplished by means of a calibration curve, which itself may be implemented in programmed form, in software, hardware or firmware.
[0063] The present invention also, in a further aspect, relates to a device or apparatus appropriate, especially adapted or equipped, e.g. programmed and comprising the means, for executing a method according to any of the invention aspects and
embodiments defined herein.
[0064] In embodiments of the invention, the invention relates to an apparatus (device) comprising at least one acoustic transducer pair, and at least one position sensing device or means for determining the position of a material which is in the form of a solid particle or a liquid droplet. The position sensing device preferably is an optical system, especially comprising a high-speed image capture device, for example a digital imaging system.
[0065] In some embodiments, the apparatus for acoustic levitation comprises a material input system, also sometimes referred to as a singulation system or element. Such material input system may, for example, be a container with the material (which may already be in particle or droplet form, e.g. in the form of a fluid bed (maintained by gas and/or ultrasound) or spouted bed, a microfluidic element allowing to feed droplets of material, a micro cup, a funnel or the like.
[0066] The apparatus, according to any one of the invention embodiments defined herein, further preferably comprises a material transport system or element for shifting the position of the material within an acoustic node to another location, for example a container. In embodiments of the invention, the material transport system comprises an acoustic aperture. As used herein, a material transport system may be used to refer to either or both of shifting material to a different location, or dispensing.
[0067] The apparatus according to any one of the preceding embodiments may, in a further invention embodiment, comprise a material collecting device or means to collect material positioned, characterized and/or weighed in an acoustic node. This material collecting means may be a device or a container. The material collecting device may be passive, or may be an active device.
[0068] Embodiments of the apparatus and method of the invention can be used in conjunction with generating a material with a certain (e.g. , desired) size and morphology, for example by crystallizing or precipitating from a solvent or anti-solvent. In such
embodiments, material may be crystallized or precipitated in situ within the levitating node, or may be precipitated or crystallized conventionally and fed directly into a bulk dispenser for subsequent singulation. This can eliminate conventional processing steps such as milling, and thus may be more efficient with both respect to material and processing time. Such an in situ crystallization or precipitation may also eliminate undesirable chemical or pharmacological impurities and/or undesirable solid state polymorphs which can occur during conventional manufacturing, as well as mitigating or eliminating processing and material transportation errors.
[0069] Embodiments of the apparatus and method of the invention afford advantages in manufacturing, for example in fixed dose manufacturing wherein the present invention affords consistency and reliability and can improve homogeniety. In particular, various dosage strengths may be readily manufactured and without the need for revalidation efforts. The use of the present invention in manufacturing also can eliminate the need to mechanically weigh active materials, and in particular when dispensing small doses of highly potent materials, can eliminate requirements for mixing actives with excipients, and consequently heterogenous material errors.
[0070] Embodiments of the system and method of the present invention offer point of care manufacturing capability at a hospital, pharmacy or medical center, thus avoiding high levels of inventory of drug product in distribution sites, packaging process and costs of an analytical testing during and after manufacture, and further can eliminate the need for identity testing after packaging.
[0071] The definitions given in the following may be applied as appropriate or desired to replace one or more or all general terms of each invention aspect or embodiment in which they appear by the more specific definitions, thus further defining specific and preferred invention embodiments.
[0072] Unless otherwise clear from the context, the terms "aspect" and "embodiment" including their plurals, are used interchangeably.
[0073] Where a "material" is mentioned, this especially refers to a (relatively small) portion. A material may be either solid, semi-solid, or liquid, and in the form of a particle or droplet.
[0074] "Particle" in particular means a (under the temperature conditions during application of a method or device according to the invention) solid material that may be a
monolithic particle or an aggregate of solid material sub-particles, e.g. a granulate or agglomerate. The term "particle" may include nanoparticles.
[0075] "Droplet" in particular means a material with a (under the temperature conditions during application of a method or device according to the invention) liquid continuous matrix which is the sole phase present, or they may comprise solid material (including entrapment material) as non-continuous phase, e.g. as a suspension, or immiscible liquid material, e.g. sub-droplets, e.g. in a water-in-oil or oil-in-water emulsion. Droplets may be disrupted into sub-droplets or they may be united to form larger droplets in the acoustic field or when dispensed into a container or device.
[0076] A "micelle" material is especially one comprising supermolecular colloid particles, often including a packet of chain molecules in parallel arrangement, e.g. formed from surface active (amphiphilic) substances.
[0077] A "liposome" material is especially a material comprising spherical vesicles having at least one lipid bilayer, and may have a single, or multiple concentric or nonconcentric chambers.
[0078] A "nanosphere" or "microsphere" material is especially a hollow material comprising a spherical shell.
[0079] A "nanocapsule" or "microcapsule" material is especially a liquid core material surrounded by a membrane.
[0080] A "nanobead" or "microbead" material is especially a solid core material surrounded by a shell or coating.
[0081] A "viral material" may e.g. be formed from proteins and/or nucleic acids which at least partially correspond to proteins and/or nucleic acids in virus, or genetically modified variants thereof, or complete virus (which may be inactivated e.g. for vaccination purposes).
[0082] A "cell component" may e.g. comprise membrane vesicles from organelle or the outer membrane of cells, or complete organelles, such as mitochondria.
[0083] A "cell material" preferably comprises a material comprising one or more cells, such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes, e.g. cells allowing to provide monoclonal antibodies.
[0084] An "optical system" (or "optical unit or element") may be any system, device, component or arrangement which utilizes some form of electromagnetic radiation to
detect a physical object. Examples of an optical system comprise a camera or a laser detection system. A camera system is preferably a high speed camera system. A "camera" is an optical instrument allowing recording of images (single images or sequences of images, e.g. in the form of videos or movies) which may be stored, transmitted to another location, or both. A digital camera (also referred to as a digital imaging system) is one preferred embodiment. The camera may work with the light of the visible spectrum or with other portions of the electromagnetic spectrum, e.g. UV light. Suitable imaging protocols include, for example, optical coherence tomography, phase contrast and differential interference contrast microscopy, angle-resolved low-coherence interferometry and phase-contrast X-ray imaging. The optical system preferably has a resolution sufficient to be able to adequately image and characterize particles of the size desired, for example those in the 10 to 20 micron size range. In embodiments of the invention, a magnification of the optical system is preferably around 400 times, or greater. A focal length of the system is of a nature such that the lens remains out of the acoustic levitation field.
[0085] Generally, in embodiments of the present invention, a digital imaging system has three components; an image sensor, a lens and body, and software for processing the image. The image sensor is a digital integrated circuit that senses light projecting onto the surface of the device. The light is converted into electrical digital pixels. The pixels are arrayed and sent to the software for processing into an image on a computer monitor. Light enters the lens and travels through the body to the digital image sensor. Two important parameters of the imaging system are magnification and focal length. The magnification is the ability of the lens, image sensor, and software to increase the viewable size of the object. The focal length is the distance from the object to the lens. The lens must be far enough away from the acoustic field so as not to interfere with the acoustic standing wave in any way while providing sufficient focal range to bring the object into focus for imaging. In embodiments of the invention, a focal length may be at least 50 mm from the lens to the edge of the transducer to prevent interference with the acoustic standing wave. The magnification requirement for the levitation system should be sufficient to clearly resolve the smallest size particle being weighed by the apparatus. For example, a 20um diameter particle preferably takes a minimum resolution of 100x100 pixels at 100x magnification to produce a ½" object on a 10"x10" image on the
monitor screen with a 5 megapixel image sensor. This magnification provides sufficient resolution to measure the levitation height of the 20um particle.
[0086] A "laser detection system" is any laser system that allows determining distances or positions of materials, or any other properties thereof, such as its surface properties, refractive index, density or the like. Examples are laser measuring devices or laser interferometers.
[0087] In addition to determining a particle's weight, in embodiments of the invention a particle characterization system may be supplied to determine properties and characteristics of a particle for example size, shape, density, surface properties, refractive index, spectral properties (e.g. infrared or raman) and others. Such a particle characterization system may also function as an optical detection system for determining particle position, or may be independent of or in addition to a particle position detection system. Laser detection systems can be used both as a particle position detection system and is a particle characterization system. Other systems which may be primarily particle characterization includes optical systems which utilize a speckle decorrelation our time of flight algorithm. Such systems allow, for example, so the testing of the kind of surface of a solid or liquid material according to the invention embodiments and make it possible to achieve high precision examination of surface topography.
[0088] Characterization of a particle, as used herein, includes determining shape, size, morphology, surface texture, rugosity density and weight. Such features are properties of a particle may be additionally used to classify, sort, or dispense. By applying an acoustic wave at any angle to the levitation wave, particles may be rotated, turned or aligned in a particular manner, and ultimately transferred or dispensed based upon such alignment and/or characterization features. Thus, the standing acoustic levitating wave may be viewed as having an angle of 0° (purely vertical), and the angled acoustic wave may be positioned anywhere between 0 and 180°. Multiple angled waves may be employed to particular benefit. The angled wave may sometimes be referred to herein as a wave having a transverse component, or a transverse wave. In some embodiments, the transverse wave is orthogonal to the levitating wave.
[0089] In embodiments of the invention, application of a transverse of wave can rotate a levitated particle, that is, change its orientation, which can assist in obtaining a better image by the optical detection system. Additionally, a transverse wave may be employed to position a particle within a standing node, thus enabling the apparatus to
perform an operation on the particle. For example repositioning a particle within the standing node may enable the optical detection system to better focus thereon. In embodiments of the invention, a transverse wave may be used to manipulate or extract particles having a specific response thereto. For example application of a transverse wave may be used to reposition and thereby deselect or reject particles which are nonuniform or which have a shape which is not desired.
[0090] The term "dispense" or "dispensing" of a material especially relates to its contactless transfer to and deposition at a desired destination. Thus in embodiments of the invention, the material (e.g. particle or droplet) can be delivered in a precise amount and/or with precise characterization knowledge to a desired destination, without the need for the material to contact (or be contacted by) any intermediate surfaces other than those at the destination.
[0091] The term "food product" comprises, for example, a "nutraceutical" (sometimes also called "Functional Food", "Functional Food product", "Foodsceutical", "Medicinal Food" or "Designer Food") and, according to the present invention embodiments, is defined as food product (including beverages) suitable for human consumption - the expression comprises any fresh or processed food having a health-promoting and/or disease-preventing property beyond the basic nutritional function of supplying nutrients, including food made from functional food ingredients or fortified with health-promoting additives, especially with an effects in the prophylaxis or treatment of one or more of the disorders mentioned herein, in which a material obtained (especially dispensed) according to the invention is added as an ingredient (especially as additive) as health benefit agent, especially in an effective amount, as well as any partially or totally artificially composed food.
[0092] The nutraceuticals can alternatively be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions, suspensions, parenteral products (e.g. intra venous infusions or injects or subcutaneous injects) or the like.
[0093] The term "pharmaceutical formulation" (medicament) comprises any type of formulation known in the art. Said formulation may comprise one or more drugs ("active ingredients") with or without (pharmaceutically acceptable) excipient(s).
[0094] Drugs comprise, for example, antibodies, antibody fragments, nucleic acids, peptides, vaccines, enzymes, small molecules, organic drugs or other therapeutically active molecules.
[0095] The active ingredient(s) may, for example, comprise (non-limiting) 5-alpha- reductase inhibitors, 5-aminosalicylates, 5HT3 receptor antagonists, AACE inhibitors with calcium channel blocking agents, ACE inhibitors with thiazides, adamantane antivirals, adrenal cortical steroids, adrenal corticosteroid inhibitors, adrenergic bronchodilators, agents for hypertensive emergencies, agents for pulmonary hypertension, aldosterone receptor antagonists, alkylating agents, allergenics, alpha- glucosidase inhibitors, alternative medicines, amebicides, aminoglycosides, aminopeni- cillins, aminosalicylates, AMPA receptor antagonists, amylin analogs, analgesic combinations, analgesics, androgens and anabolic steroids, angiotensin converting enzyme inhibitors, angiotensin II inhibitors with calcium channel blockers, angiotensin I I inhibitors alone or with thiazidesangiotensin receptor blockers, angiotensin receptor blockers and neprilysin inhibitors, anorectal preparations, anorexiants, antacids, anthelmintics, anti- angiogenic ophthalmic agents, anti-CTLA-4 monoclonal antibodies, anti-infectives, antiadrenergic agents (central), e.g. with thiazides, antiadrenergic agents (peripheral), e.g. with thiazides, antiadrenergic agents, centrally acting antiadrenergic agents, peripherally acting antiandrogens, antianginal agents, antiarrhythmic agents, antiasthmatic combinations, antibiotics/antineoplastics, anticholinergics, antiemetics, anticholinergic antipar- kinson agents, anticholinergic bronchodilators, anticholinergic chronotropic agents, anticholinergics/antispasmodics, anticoagulants, anticonvulsants, antidepressants, antidiabetic agents, antidiabetic combinations, antidiarrheals, antidiuretic hormones, antidotes, antiemetic/antivertigo agents, antifungals, antigonadotropic agents, antigout agents, antihistamines, antihyperlipidemic agents, antihyperlipidemic combinations, antihypertensive combinations, antihyperuricemic agents, antimalarial agents, antimalarial combinations, antimalarial quinolones, antimetabolites, antimigraine agents, antineoplastic detoxifying agents, antineoplastic interferons, antineoplastics, antiparkinson agents, antiplatelet agents, antipseudomonal penicillins, antipsoriatics, antipsychotics, antirheumatics, antiseptics and germicides, antithyroid agents, antitoxins and antivenins, antituberculosis agents, antituberculosis combinations, antitussives, antiviral agents, antiviral boosters, antiviral combinations, antiviral interferons, anxiolytics, sedatives, hypnotics, aromatase inhibitors, atypical antipsychotics, azole antifungals, bacterial vaccines,
barbiturate anticonvulsants, barbiturates, BCR-ABL tyrosine kinase inhibitors, benzodiazepine anticonvulsants, benzodiazepines, beta blockers with calcium channel blockers, beta blockers with thiazidesbeta-adrenergic blocking agents, beta-lactamase inhibitors, bile acid sequestrants, biologicals, bisphosphonates, bone morphogenetic proteins, bone resorption inhibitors, bronchodilator combinations, bronchodilators, calcineurin inhibitors, calcitonin, calcium channel blocking agents, carbamate anticonvulsants, carba- penems, carbonic anhydrase inhibitor, anticonvulsants, carbonic anhydrase inhibitors, cardiac stressing agents, cardioselective beta blockers, cardiovascular agents, catecholamines, CD20 monoclonal antibodies, CD30 monoclonal antibodies, CD33 monoclonal antibodies, CD52 monoclonal antibodies, central nervous system agents, cephalosporins, cerumenolytics, CFTR combinations, CFTR potentiators, chelating agents, chemo- kine receptor antagonists, chloride channel activators, cholesterol absorption inhibitors, cholinergic agonists, cholinergic muscle stimulants, cholinesterase inhibitors, CNS stimulants, coagulation modifiers, colony stimulating factors, contraceptives, corticotropin, coumarins and indandionescox-2 inhibitors, decongestants, dermatological agents, diagnostic radiopharmaceuticals, diarylquinolines, dibenzazepine anticonvulsants, digestive enzymes, dipeptidyl peptidase 4 inhibitors, diuretics, dopaminergic antiparkinsonism agents, drugs used in alcohol dependence, echinocandins, EGFR inhibitors, estrogen receptor antagonists, estrogens, expectorants, factor Xa inhibitors, fatty acid derivative anticonvulsants, fibric acid derivatives, first generation cephalosporins, fourth generation cephalosporins, functional bowel disorder agents, gallstone solubilizing agents, gamma- aminobutyric acid analogs, gamma-aminobutyric acid reuptake inhibitors, gastrointestinal agents, general anesthetics, genitourinary tract agents, Gl stimulants, glucocorticoids, glucose elevating agents, glycopeptide antibiotics, glycoprotein platelet inhibitors, glycylcyclines, gonadotropin releasing hormones, gonadotropin-releasing hormone antagonists, gonadotropins, group I antiarrhythmics, group II antiarrhythmics, group III antiarrhythmics, group IV antiarrhythmics, group V antiarrhythmics, growth hormone receptor blockers, growth hormones, guanylate cyclase-C agonists, H. pylori eradication agents, H2 antagonists, hedgehog pathway inhibitors, hematopoietic stem cell mobilizer, heparin antagonists, heparins, HER2 inhibitors, herbal products, histone deacetylase inhibitors, hormones, hormones/antineoplastics, hydantoin anticonvulsants, hydrazide derivatives, illicit (street) drugs, immune globulins, immunologic agents, im- munostimulants, immunosuppressive agents, impotence agents, in vivo diagnostic bio-
logicals, incretin mimetics, inhaled anti-infectives, inhaled corticosteroids, inotropic agents, insulininsulin-like growth factor, integrase strand transfer inhibitor, interferons, interleukin inhibitors, interleukins, intravenous nutritional products, iodinated contrast media, ionic iodinated contrast media, iron products, ketolides, laxatives, leprostatics, eukotriene modifiers, lincomycin derivatives, local injectable anesthetics, loop diuretics, lung surfactants, lymphatic staining agents, lysosomal enzymes, macrolide derivatives, macrolides, magnetic resonance imaging contrast media, mast cell stabilizers, megliti- nides, metabolic agents, methylxanthines, mineralocorticoids, minerals and electrolytes, miscellaneous agents, miscellaneous analgesics, miscellaneous antibiotics, miscellaneous anticonvulsants, miscellaneous antidepressants, miscellaneous antidiabetic agents, miscellaneous antiemetics, miscellaneous antifungals, miscellaneous antihyperlipidemic agents, miscellaneous antihypertensive combinations, miscellaneous antimalarials, miscellaneous antineoplastics, miscellaneous antiparkinson agents, miscellaneous antipsychotic agents, miscellaneous antituberculosis agents, miscellaneous antivirals, miscellaneous anxiolytics, sedatives and hypnotics, miscellaneous bone resorption inhibitors, miscellaneous cardiovascular agents, miscellaneous central nervous system agents, miscellaneous coagulation modifiers, miscellaneous diagnostic dyes, miscellaneous diuretics, miscellaneous genitourinary tract agents, miscellaneous Gl agents, miscellaneous hormones, miscellaneous metabolic agents, miscellaneous ophthalmic agents, miscellaneous otic agents, miscellaneous respiratory agents, miscellaneous sex hormones, miscellaneous topical agents, miscellaneous uncategorized agents, miscellaneous vaginal agents, mitotic inhibitors, monoamine oxidase inhibitors, mouth and throat products, rmTOR inhibitors, mucolytics, multikinase inhibitors, muscle relaxants, mydriatics, narcotic analgesic combinations, narcotic analgesics, nasal anti-infectives, nasal antihistamines and decongestants, nasal lubricants and irrigations, nasal preparations, nasal steroids, natural penicillins, neprilysin inhibitors, neuraminidase inhibitors, neuromas- cular blocking agents, neuronal potassium channel openers, next generation cephalosporins, nicotinic acid derivatives, NK1 receptor antagonists, NNRTIs, non-cardioselec- tive beta blockers, non-iodinated contrast media, non-ionic iodinated contrast media, non-sulfonylureas, nonsteroidal anti-inflammatory agents, NS5A inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs), nutraceutical products, nutritional products, ophthalmic anesthetics, ophthalmic anti-infectives, ophthalmic anti-inflammatory agents, ophthalmic antihistamines and decongestants, ophthalmic diagnostic agents, ophthalmic
glaucoma agents, ophthalmic lubricants and irrigations, ophthalmic preparations, ophthalmic steroids, ophthalmic steroids with anti-infectives, ophthalmic surgical agents, oral nutritional supplements, other immunostimulants, other immunosuppressants, otic anesthetics, otic anti-infectives, otic preparations, otic steroids, otic steroids with anti-infectives, oxazolidinedione anticonvuls, antsoxazolidinone antibiotics, parathyroid hormone and analogs, PCSK9 inhibitors, penicillinase resistant penicillins, penicillins, peripheral opioid receptor antagonists, peripheral vasodilators, peripherally acting antiobesity agents, phenothiazine antiemetics, phenothiazine antipsychotics, phenylpiperazine antidepressants- phosphate binders, plasma expanders, platelet aggregation inhibitors, platelet-stimulating agents, polyenes, potassium sparing diuretics with thiazidespotas- sium-sparing diuretics, probiotics, progesterone receptor modulators, progestinsprolactin inhibitors, prostaglandin D2 antagonists, protease inhibitors, protease-activated recep- tor-1 antagonists, proteasome inhibitors, proton pump inhibitors, psoralens, psychotherapeutic agents, psychotherapeutic combinations, purine nucleosides, pyrrolidine anticonvulsants, quinolones, radiocontrast agents, radiologic adjuncts, radiologic agents, radiologic conjugating agents, radiopharmaceuticals, recombinant human erythropoietins, renin inhibitors, respiratory agents, respiratory inhalant products, rifamycin derivatives, salicylates, sclerosing agents, second generation cephalosporins, selective estrogen receptor modulators, selective immunosuppressants, selective phosphodiesterase^ inhibitors, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, serotoninergic neuroenteric modulators, sex hormone combinations, sex hormones, SGLT-2 inhibitors, skeletal muscle relaxant combinations, skeletal muscle relaxants, smoking cessation agents, somatostatin and somatostatin analogs, spermicides, statins, sterile irrigating solutions, streptomyces derivatives, succinimide anticonvulsants, sulfonamides, sulfonylureas, synthetic ovulation stimulants, tetracyclic antidepressants, tetracyclines, therapeutic radiopharmaceuticals, therapeutic vaccines, thiazide diuretics, thiazolidine diones, thioxanthenes, third generation cephalosporins, thrombin inhibitors, thrombolytics, thyroid drugs, TNF alfa inhibitors, tocolytic agents, topical acne agents, topical agent, stopical anesthetics, topical anti-infectives, topical anti-rosacea agents, topical antibiotics, topical antifungals, topical antihistamines, topical antineoplastics, topical antipsoriatics, topical antivirals, topical astringents, topical debri- ding agents, topical depigmenting agents, topical emollients, topical keratolytics, topical non-steroidal anti-inflammatories, topical photochemotherapeutics, topical rubefacient,
topical steroids, topical steroids with anti-infectives, triazine anticonvulsants, tricyclic antidepressants, trifunctional monoclonal antibodies, ultrasound contrast media, upper respiratory combinations, urea anticonvulsants, urea cycle disorder agents, urinary anti- infectives, urinary antispasmodics, urinary pH modifiers, uterotonic agents, vaccine combinations, vaginal anti-infectives, vaginal preparations, vasodilators, vasopressin antagonists, vasopressors, VEGF/VEGFR inhibitors, viral vaccines, viscosupplementation agents, vitamin and mineral combinations, and vitamins. These diseases are from the Drug Class Database of the FDA and are non-limiting.
[0096] Embodiments of the present invention relate to pharmaceutical formulations or compositions that comprise an active ingredient as or included in a material obtained (e.g. dispensed) according to the invention and that can be used especially in the treatment of a disease or condition.
[0097] The material of the present invention may be used, for example, for the preparation of pharmaceutical compositions that comprise a pharmaceutically effective amount of the material.
[0098] The active ingredient in said material may be present in free form or in the form of a pharmaceutically acceptable salt, solvate, hydrate or polymorph, or in admixture with a significant amount of one or more inorganic or organic, solid or liquid,
pharmaceutically acceptable excipients (carriers).
[0099] Compositions for enteral administration, such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, to warm-blooded animals, especially humans, are especially preferred. The compositions comprise the active ingredient alone or, preferably, together with a pharmaceutically acceptable excipient (carrier). The dosage of the active ingredient depends upon the disease to be treated and upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, and the mode of administration.
[00100] The pharmaceutical compositions may comprise from approximately 0.0001 % to approximately 100% (% referring to weight percent) active ingredient. Single-dose administration forms may comprise, in embodiments herein, from approximately 0.001 % to approximately 100% active ingredient and forms that are not of single-dose type may comprise, in embodiments herein, from approximately 5% to approximately 20% active ingredient. Unit dose forms are, for example, coated and uncoated tablets, ampoules,
vials, suppositories, sachets, sprinkles, spray containers or capsules. Further dosage forms are, for example, ointments, creams, pastes, foams, tinctures, sprays, etc.
Examples are capsules or tablets or ampoules containing from about 0.0001 mg to about 1 .0 g, e.g. from 0.001 to 5 mg material dispensed according to the invention embodiments.
[00101]The pharmaceutical compositions of the present invention are, taking reference to the inventive weighing, characterizing, manipulating or dispensing, may otherwise be prepared in a manner as known to the art, for example by means of conventional mixing, granulating, coating, dissolving or lyophilizing processes or by a method or device according to the present invention, or by a combination of conventional preparing and methods of the present invention.
[00102] Embodiments of the present invention comprise solutions of the material with the active ingredient, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example in the case of lyophilized compositions comprising the active ingredient alone or together with a carrier can be made up before use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes. The said solutions or suspensions may comprise viscosity- increasing agents or solubilizers, such as sodium carboxymethylcellulose, carboxy- methylcellulose, dextran, polyvinylpyrrolidone or gelatin.
[00103] Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes. There may be mentioned as such especially liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to 22, especially from 12 to 22, carbon atoms, for example lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brasidic acid or linoleic acid, if desired with the addition of antioxidants, for example vitamin E, β-carotene or 3,5-di-tert-butyl-4-hydroxytoluene. The alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is a mono- or poly-hydroxy, for example a mono-, di- or tri-hydroxy, alcohol, for example methanol, ethanol, propanol, butanol or pentanol or the isomers thereof, but especially
glycol and glycerol. The following examples of fatty acid esters are therefore to be mentioned: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M 2375" (polyoxy- ethylene glycerol trioleate, Gattefosse, Paris), "Miglyol 812" (triglyceride of saturated fatty acids with a chain length of C8 to C12, Huls AG, Germany), but especially vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
[00104] Injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers. In embodiments of the invention, the process may be coupled directly to a filling device under sterile conditions such that as a particle is weighed and/or characterized, it may be directly and contactlessly introduced into an ampoule or vial. By use of the term "contactless" it is meant that no human contact is required and minimal or no machine or surface contact, as once levitated, the particle may be directly transferred to its final destination, such as an ampoule or vial.
[00105] Pharmaceutical compositions for oral administration which are also especially preferred can be obtained by combining the material with the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragee cores or capsules. It is also possible for them to be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts.
[00106] Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using for example corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, and/or carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. Excipients are especially flow
conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic
solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phtha- late. Capsules are dry-filled capsules made of gelatin or HPMC and soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilizers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added. Dyes or pigments may be added to the tablets or dragee coatings or the capsule casings, for example for identification purposes or to indicate different doses of active ingredient.
[00107] Tablet cores can be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations.
[00108] Pharmaceutical compositions for oral administration also and especially include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer. The hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, binders, and/or glidants, and optionally stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquid excipients, to which stabilizers and detergents may also be added.
[00109] Pharmaceutical compositions suitable for rectal administration are, for example, suppositories that consist of a combination of the active ingredient and a suppository base.
[00110] For parenteral administration, aqueous solutions of an active ingredient in water- soluble form, for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers, are especially suitable. The active ingredient, optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents.
[00111] Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions.
[00112] As used herein, the term "excipient" especially refers to any pharmaceutically or nutraceutically acceptable carrier material as already mentioned and also and includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g. , antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art. Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
[00113] The term "a therapeutically effective amount" especially refers to an amount of the material obtainable according to the present invention (especially the active ingredient forming it or comprised in it) that will elicit the biological or medical response of a subject suffering from a disease or disease symptoms, including ameliorating the status of a subject suffering from said disease, alleviating the disease or one or more of its symptoms, or preventing the disease, or the like. As used herein, the term "subject" refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g. , humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is in particular a human.
[00114] The dosage of a material obtained (e.g. dispensed) or characterized according to the invention embodiments in pharmaceutical preparations and food products may vary according to the patient's needs, status and condition. For example, a daily dosage (which may be split up into two or more, e.g. up to three dosage units) may be in the range from 0.0001 mg to 10,000 mg, such as from 0.001 to 5 mg, e.g. from 0.001 to 1 mg.
[00115] Placebo formulations may comprise solely the excipient material(s) and may be useful in the placebo treatment or in clinical trials.
[00116] Diseases (including disorders) may, for example, comprise infectious and parasitic diseases, especially lower respiratory tract infections, diarrhea, AI DS, tuberculosis, and malaria; neuropsychiatric conditions, e.g. depression; injuries, especially motor vehicle accidents, cardiovascular diseases, heart attacks and stroke,
premature birth and other perinatal deaths, gastrointestinal disorders, and cancer. Any disease or disorder is encompassed by these general terms.
[00117] Where "intermediate" is referred to, this relates to any compound which is used as starting material or intermediate in the synthesis of a final drug molecule. Examples are organic low molecular weight compounds, enzymes, antibodies or specifically binding parts thereof, nucleic acids or nucleic acid derivatives, such as siRNA, or the like, especially selected from the active ingredients mentioned above.
[00118] In accordance with the foregoing, the present invention also comprises the following embodiments, each of which can be claimed:
[00119] A material obtained (especially weighed, characterized and/or dispensed) according to the invention for use in the diagnostic or especially therapeutic (including prophylactic) treatment of an animal, preferably a mammal, especially a human; especially of any one or more of the particular disorders set forth herein.
[00120] A pharmaceutical or neutraceutical composition comprising a material obtained (especially weighed, characterized and/or dispensed) according to a method of the invention as active ingredient together with a pharmaceutically acceptable diluent or carrier, especially for use in the therapeutic and/or prophylactic treatment of a disease or disorder, e.g. mentioned herein.
[00121] A method for the treatment of a disorder, especially any one or more disorders, e.g. as set forth herein, in a subject in need of such treatment, comprising administering a pharmaceutically effective amount of a material obtained (especially weighed, characterized and/or dispensed) according to a method of the invention, especially to an individual in need thereof.
[00122] The use of a material obtained (especially weighed, characterized and/or dispensed) according to a method of the invention, for the manufacture of a medicament, nutraceutical, or food supplement for the treatment or prevention of a disease or disorder e.g. as mentioned herein.
[00123]A method as defined above comprising co-administration, e.g. concomitantly or in sequence, a therapeutically effective amount of a material obtained (especially weighed, characterized and/or dispensed) according to a method of the invention, and a different pharmaceutically active compound and/or a pharmaceutically acceptable salt thereof, said different pharmaceutically active compound and/or salt thereof being especially for use in the treatment of any one or more of the disorders set forth herein.
[00124] A combination product comprising a therapeutically effective amount of a material obtained (especially weighed, characterized and/or dispensed) according to a method of the invention, and a different pharmaceutically active compound and/or a
pharmaceutically acceptable salt thereof, said second pharmaceutically active compound being especially for use or of use in the treatment of any one or more of the particular disorders set forth hereinbefore.
[00125] In many embodiments, the invention comprises at least one acoustic transducer pair; together with at least one position sensing means for determining the position of a material which is in the form of a solid particle or a liquid droplet. This apparatus is preferably (e.g. computer) programmed or can be (e.g. computer) programmed to allow to determine the position of the material to be weighed and to use the position information to determine the weight of said material.
[00126] Referring to Figure 1 , an apparatus 10 illustrating the principle of acoustic levitation is represented. A transducer 12 and a reflector 14 are positioned to be coaxial about a center axis AA at a distance that allows an acoustic standing wave to be formed between them. A material (here in a non-limiting way - a particle 16) is held in a hovering position (in levitation) within a capture node 18 (also sometimes referred to as a positive pressure node, and/or a positive sound pressure zone) of a standing acoustic pressure wave 20. Standing wave 20 is comprised of a direct acoustic wave 20a, and a corresponding reflected acoustic wave 20b. Direct and reflected acoustic waves 20a and 20b are essentially superimposed over one another. However solely for clarity in the Figure the two are shown slightly displaced from one another. Wave 20 represents the relative amplitude of the sound pressure relative to ambient pressure. When viewing the Figure, the portion of wave 20 left of center axis AA represent an acoustic pressure range from positive to ambient and the portion of the wave 20 right of axis AA represent an acoustic pressure range from negative to ambient. The capture node 18 is the zone in which particle levitation occurs, and is defined by the region BB as shown in the Figure. The capture node 18 is a subset (in this example, the upper half) of a positive pressure zone 24 formed within region CC in the Figure. Generally, capture node 18 is bounded by a midpoint (viewed along axis AA) of the capture zone 18 and a zero pressure boundary 25 above. A zero pressure boundary 25 (also referred to as an anti- node) is found at each point wherein the standing acoustic wave 20 intersects with the center axis AA.
[00127] Thus, the particle 16 is kept in the capture node 18 (levitation zone) by acoustic pressure. For a given acoustic pressure level (above the threshold required to levitate a particle), a particle having a relatively higher weight will sink lower in the capture node 18 compared to a relatively lighter particle. Put alternately, the heavier the particle, the higher the pressure is required to keep it in a fixed hovering position. If the particle is (e.g. by shift of the position of the node 18 or by decreasing the energy of the sound wave) reaching the lower half of the node 18, it may drop through this lower part (with declining pressure) and antinode 25 and then be held by the next node 18 in a hovering position or drop e.g. through a hole in the transducer to a desired destination. This is one exemplary way to deliver a material without touching (hence contactless) and thus preventing or mitigating contamination or otherwise unwanted surface contact as the particle 16 is delivered to a desired destination. In particular, contactless dispensing is a benefit for materials which require special containment environments to prevent contamination of material/and or of containment, for example with toxic and or radioactive materials.
[00128] Figure 2 shows an example for the measured sound level for an actually established standing acoustic wave (the sound pressure level profile in the particle levitator for one set of operating conditions actually used). A capture node 18 and an antinode 25 of the sound pressure wave 20 and their height relative to a datum (a maximum sound pressure position, i.e. a node) are shown. For Figure 2, the datum was based upon the top surface of the transducer. The sound pressure level can, for example, be determined with a sound pressure calibration sensor (see Figure 4). Figure 2 represents measurements of the sound pressure level within the standing acoustic wave. The sound pressure amplitude follows a sinusoidal shape which matches the electrical signal used to drive the transducer. Real world effects, including but not limited to, sound harmonics from the transducer, air pressure variation, and ambient noise levels should be considered when calibrating the system to achieve accurate weight measurements.
[00129] Figure 3 depicts a graph of levitation height above a datum versus weight, wherein levitation height corresponds to the particles weight (according to an embodiment of the invention). In the Figure, the X axis represents distance from the datum in millimeters and the Y axis is weight in kilograms. For a given sound pressure, the particles levitate at different heights depending on their size and hence weight. The
particles levitate at the height at which acoustic pressure forces are balanced by the force of gravity. The "y" equation defines the line and R2 refers to a statistical measure.
[00130] Therefore, in embodiments in the invention, a calibration curve (represented in Figure 3) is established by actually determining the material's (droplet or particle) position relative to a datum. The datum is a predetermined location - for example the surface of the transducer - and can be used for a range of particles with known weights to generate a calibration plot. Calibration (and consequent weight determination) may be accomplished using particles or droplets, or combinations thereof.
[00131] In order to perform a calibration, in the example represented in Figure 3 several different particle diameters were levitated within the acoustic particle levitator at the same time. The nominal particle diameters used were 20 μηη, 50 μηη and 100μηι. The sizes of all three particle species were known because they are N IST-standard calibration particles of known weight and density (and hence weight) to within 1 %. This information was provided by the manufacturers: Thermo Scientific and Cospheric. These particle diameters were chosen based upon a particle size range of interest, and do not represent the maximum or minimum particle diameters that can be levitated.
[00132] In one embodiment of the invention, weight of a particle is determined by determining the vertical position, that is, a height of the particle relative to a lower sound transducer surface or any other reference height or datum, and comparing the determined height to a calibration plot in order to determine the weight of the particle.
[00133] It is also within the scope of the present invention to change the strength of the acoustic field in order to change the position of the material to a specific height and to determine the weight by setting it in relation to the strength of the acoustic field, as defined, for example, by an audio detection system, or to use a combination of any of the methods mentioned herein for determining the weight of a material.
[00134] Additionally, or alternatively also theoretical predictions of the weight/height (position) of the material particles can be used (e.g. weight can be based on a determination of the sound pressure level at specific heights), or by combinations of calibration and theoretical prediction. In aspects of the system and method, an audio detection system may comprise a microphone or other sound sensing means as a sensing element, and sound pressure may be measured periodically or continuously. By this method, sound pressure stability can be used as an internally calibrated method to accurately weigh particles. For example, a target sound pressure may be determined
experimentally or by reference to an external standard, and this target sound pressure is maintained via a microphone or sound sensing element coupled to an appropriate internal electronic control system.
[00135] Where a material is "dispensed" into one or more destinations in accordance with one or more of the methods of the invention, this allows for the delivery of a very precise weight amount to the destination, and/or for the delivery of an otherwise characterized material, as mentioned above and below. A destination may be ultimate or final, that is, the end product of the method or process, or intermediate, that is some point before the ultimate or final point in the method or process. Such dispensing is useful for materials which require precise weighing a small amounts for example certain biological materials as well as certain highly potent materials. Embodiments of the invention provide methods and apparatus for dispensing genetic and biomarker materials and products that enable a specific dose and regimen for a specific individual, and further which can be performed in a highly automated manner. Embodiments of the invention also provide consistent product benefits when used with or in novel drug delivery systems which otherwise require a matrix or formulation of very small amounts of material.
[00136] A device or container as final destination may comprise a device that allows for the distribution into a unit form of a pharmaceutical preparation, e.g. a container as mentioned in the following, and may e.g. be an ampoule filling, capsule filling or tablet forming device; a container may e.g. be selected from a capsule, an ampoule, a syringe, a bottle, an infusion container, a sachet, a vial and a blister pack.
[00137] A device or container as further destination may comprise a device or container that is useful or necessary for some further processing, distribution or handling of the material as an intermediate prior to achieving the final unit form of a pharmaceutical preparation, and may e.g. comprise a filling, transporting, or conditioning device; a container may e.g. be selected from a well, capsule, ampoule, syringe, bottle, infusion container, sachet, vial and blister.
[00138] In embodiments of the invention, material is shifted to the destination by using multiple sound transducers, which may make use of superimposition of acoustic waves, or a tuning of the waves so that together, at least during the dispensing of a material in liquid droplet or solid particle form, sound waves are influenced and added so as to provide a force that drives the material to or above the desired position. This effect may also be obtained by moving the transducers of the levitating wave to a position where
the material is to be dispensed. Alternatively or in addition, superimposing a slow acoustic wave oriented in an angle different from 0° relative to the levitating wave may allow for such shift in the position of the material.
[00139] Additionally or alternatively, embodiments of the invention may use gas (e.g. air) streams or blasts, acting upon a material particle or droplet to create a force allowing the material to be dispensed or moved to a desired destination.
[00140]The dispensing method may (in addition or in combination with any one or more of the other methods appropriate, e.g. as just mentioned) comprise shifting the material to the destination by weakening or removing the acoustic levitation field, allowing the material to fall into a desired destination positioned below the material.
[00141]Alternatively or in addition, mechanical means may be used to move the material hovering in the levitation field to a desired destination. These mechanical means may include directly inserting the destination device or container in the field which may lead to a disruption that allows the hovering material to be supplied to the destination.
Alternatively or additionally, the mechanical means may comprise a manipulator, for example a robot manipulator (e.g. equipped with forceps), plungers, e.g. in rod shape, threads, wires, filaments, sheet-like materials or the like.
[00142] In embodiments of the invention, the mechanical means used to move shift or dispense the material may comprise a ratchet or conveyor belt, bar or roller that allows to position containers or devices, e.g. vials or ampoules or open capsules or the like, below a position from which the levitation field has been can be adjusted to deliver the material to them, e.g. to a position below the transducer of the apparatus in which acoustic levitation is effected, for example through a hole in said transducer.
[00143] Preferably, the dispensing takes place without need for the material to come into contact with a surface other than that in or at the destination, thus reducing risks of contamination or material loss on such surfaces.
[00144] A further aspect of the invention relates to any method described herein, comprising providing units of the materials (that is, individual particles or droplets) with an electric charge of identical polarity in order to inhibit its or their aggregation or to move or dispense them by means of electric field(s); or with an electric charge of different polarity in order to promote its or their aggregation or to move or dispense them by means of electric field(s). This allows to (e.g. also by moving the material portions towards or away from each other) to form larger particle aggregates or larger droplets. In
the case of droplets, it is possible to explode them (e.g. by administration of sufficiently strong sound waves) into smaller droplets and thus to yield smaller material droplets. Particles may also be moved by applying electrical fields, e.g. using two or more electrodes of appropriate charge.
[00145] Figure 4 shows a schematic representation of an embodiment of the apparatus 10 according to the invention that allows to both measure the material portion, e.g. particle, weight and to dispense the material to a device or container, here to capsule halves 30 on an output device 32, here in the exemplary form of a conveyor or collection device. The standing wave 20 (see Figure 1 ) in this example is produced by lower and upper sound transducers 12.
[00146] In this embodiment of the apparatus 10 a particle 16 of material (e.g. a particle or droplet of a drug material, such as an ibuprofen particle) is provided from a material introducing means 34 (here represented as an arrow). The material introducing means 34 is in communication with an input drop tube 36 which passes through a center of the upper transducer 12. The particle 16 travels via the force of gravity to one or more capture nodes 18 (as shown also in Figures 1 and 2). By varying the strength of the acoustic levitation field, the particles 16 may be delivered to a specific capture node 18. Arrow 40 represents particle flow in the Figure. Capture nodes 18 are represented schematically as ovals with a plus sign (positive pressure). Negative pressure zones, or anti-nodes, 25 are represented schematically as ovals with a negative sign. In this example, one of the capture nodes 18 may function as the weighing node, and one or more other capture nodes 18 may function to characterize the particle 16, and/or to trigger shifting or dispensing of the particle 16.
[00147] A position sensing device or system 42 (which may comprise, for example, a camera) determines the position of a material portion (e.g. particle 16) at a capture node 18 and thus provides the information required to determine its weight (e.g. from a calibration curve as shown in Figure 3). A sound pressure level calibration sensor 44 may be provided e,g, in order to allow for calibration based on sound pressure and/or to control the sound pressure. Control of sound pressure, for example, lowering the sound intensity (energy) or momentarily switching it off entirely, may be used to dispense the particle(s) to a desired destination, such as the capsule halves 30 shown
paradigmatically in Figure 4. The switching of sound energy may be controlled, for example, by appropriate switching elements and processor (not shown). In
embodiments of the invention, the apparatus is configured such that the particle may simply fall through, e.g., an output drop tube 46, disposed, for example within the central aperture of the lower transducer 12 (or reflector) and through which the material portion, e.g. particle 16, may fall without contacting the transducer 12. The output may be controlled by an optional output position sensing system (not shown) which may interface with a defective material detection device 49. If employed, the output position sensing system may serve to verify that the weighed and/or characterized particle is dispensed into the appropriate container. In embodiments of the apparatus and method of the present invention, the defective material detection device 49 may be configured to detect and to divert an out of specification particle. This aspect affords a significant benefit in enabling continuous quality control and continuous manufacturing, for example of drug particles.
[00148] Defective material (e.g. of undesired shape, size, weight, form or density) may (for example by use of a sound wave applied in a non-vertical, for example orthogonal or perpendicular direction to the standing acoustic wave 20 (represented also by nodes 18 and antinodes 25 in Figure. 4) be dispensed or transferred to a collection vessel 50 under the control of the defective material detection device 49. It is noted that detection device 49 and collection vessel 50 are shown schematically in the figure and thus not intended to be limiting in terms of position or configuration.
[00149] In addition to the position sensing system 42, and optional output position sensing system, an optional input position sensing system (not shown) may be positioned near the top of the process flow schematic, for example, near the material introducing means 34, for example, a singulation system. This input position sensing system, in embodiments of the invention, may be used to confirm particle entry.
[00150] Alternatively or additionally, in embodiments of the invention the dispensing of material portions (e.g. particles or droplets 16) may take place laterally (horizontally, e.g. perpendicular to a vertical wave axis) to a position other than the output drop tube 46. In in embodiments of the invention, this may be achieved by applying electrical field (in which case, the material portions are preferably provided in a charged form); or by superimposing a transverse sound wave configured to shift the particles laterally, or combinations thereof.
[00151] Figure 5 shows another schematic representation of the system 10 forming an embodiment of the present invention, for weighing a material particle 16, also
schematically depicting the sound pressure wave 20 and showing the particle position relative to a datum 60 which, in this example, is a position of maximum sound pressure in the corresponding capture node 18. In general, a datum may be "N" multiples of a wavelength of sound from the top surface of the transducer. "N" may thus be any whole number up to a physical maximum of about fifty. An optical position sensing system 42 is shown diagrammatically as a camera, and is used as described herein to determine the position of the material particle 16, here represented as levitating at a height x above the datum 60. A computing system 62 allows for determining the weight of the particle 16 and for controlling the system 10.
[00152] In general, devices, apparatus subsystems and means for particle introduction comprise those which achieve particle singulation, that is, in this context, selecting and introducing individual particles, as from a plurality of particles.
[00153] In aspects of the invention, one or more particles may be introduced (or singulated) by one or more mechanical, electrical, or fluidic means or devices. For example, a particle may be introduced by means of a vibrating mesh conveyor, or by a screw or auger type feed. A fluidized bed particle introducing means, or other microfluidic apparatus or device may serve as the particle introduction means or device. It is to be noted that various geometries of particle introduction may be contemplated and are within the scope of the present invention, and that particles may be introduced singly and/or multiply by acoustic manipulation, for example weighing performed as a batch process, or particles may be introduced sequentially and acoustic manipulation be performed on a continuous basis, or particles may be introduced in multiples (either single multiples are sequential multiples) and acoustic manipulation performed on the batch of particles, or sequential steps may separate multiple particles into individual manipulators. In embodiments of the invention, determination of particle characteristics such as weight may occur sequentially, in parallel, or both.
[00154] In embodiments of the invention, a device or means for particle singulation, that is the introduction of a single particle from a bulk source to enable the determination of particle weight and/or characteristics is useful for the practice of the process of the invention. Figure 6 shows an example of a particle singulation subsystem or apparatus. Additionally, Figure 6 shows a more discreet example of a subsystem or apparatus for moving and dispensing particles which have been characterized and/or weighed.
[00155] The basic elements of the apparatus 10 are as shown in Figure 1 and comprise, generally a transducer 12 and reflector 14 and associated control devices. In addition, there is a particle singulation system 70 which comprises an embodiment of the particle introduction means 34 (shown schematically in Figure 4). Particle singulation system 70 comprises a material input tank 72 which may be fitted with a cap 74 and which feeds a screw or auger feeder 76.
[00156] . Screw or auger feeder 76 is driven by a motor 78, in embodiments a stepper motor, and motor 78 is controlled by a controller 80. The output of the singulation system 70 is designed to output particles 16 sequentially, and is aligned with the input drop tube 36. In embodiments of the invention, the particle simulation system 70 may be controlled by a general or specific purpose computer, CPU or processor 81.
In Figure 6 is also shown position sensing means or unit 42, in this example, comprising an optical imaging device, communicating electrically with the computing system or computer 62. Additionally shown in this figure are details of a drive system for the transducer 12. The drive system comprises a power amplifier 84 electrically coupled to the transducer 12. A signal generator 86, which may generate a variety of waveforms supplies appropriate waveform information to the power amplifier 84. Also electrically coupled to power amplifier 84 is a power supply 88. In embodiments of the invention, the output of signal generator 86 may be controlled by a general or specific purpose computer, CPU or processor 90.
Figure 6 further illustrates one embodiment of a subsystem and method for moving and/or dispensing into a desired further or final region or container a particle 16 or a plurality of particles 16 which have been weighed and/or characterized. Thus an embodiment of the output device 32 holding a plurality of capsules 30 is illustrated. In this embodiment, the output device 32 and capsules 30 are positioned upon an X-Y gantry 100, which is one known to the art to be configured for an adopted to translate in one or more directions so as to be able to position each individual capsule 30 directly under the output drop tube 46. The output device 32 comprises a capsule tray having a plurality of capsule wells 101. In embodiments of the invention, the position of the gantry 100 with respect to output drop tube 46 may be controlled by a general or specific purpose computer, CPU or processor 104. In this embodiment, it can be seen that the weighed and/or characterized material comprising particle 16 would fall in the ordinary manner through drop tube 46 but the dispensing location is changed by virtue of the
ability to move the gantry 100, to locate each individual well 101 sequentially under the output drop tube 46. Movement of the gantry 100 may be accomplished by any means known to the art such as mechanical, electromagnetic, electrical fluidic etc.
[00157]Alternatively or additionally, multiple standing waves can be set up over a single transducer, for example by providing a sound opaque mask, also referred to herein as an acoustic aperture, having a plurality of apertures within which the standing wave is allowed the form, thus generating a number of standing wave columns above a given transducer. In embodiments of the invention, an acoustic aperture is a structure configured and designed to reduce a size of the sound field generated by the transducer pair and/or to separate the sound field into multiple parallel sound fields within a single transducer pair. An acoustic aperture is comprised of a mask of a sound reflecting material including but not limited to glass, plastic, metal, stone, or wood. The shape of the mask may be, in embodiments of the invention, congruent with the sound producing surface of the transducer, and may be for example, circular, rectangular, elliptical, or triangular. The mask is positioned in close proximity to the transducer (but not in contact) so that sound wave emissions contacting the mask in non-aperture areas are reflected back to the transducer.
[00158]The mask is placed between the transducer and the reflector or two transducers so as to reflect the sound back toward the transducer. An aperture is made through the mask to allow the sound wave emanating from the transducer to pass through the mask and move on to the reflector. When the sound wave reflects back toward the transducer from the reflector a standing acoustic wave is established through the aperture. The size and shape of the aperture is designed to reduce the size of the acoustic standing wave and contain particles in a smaller area, and may serve, for example, to ease the depth of field focusing requirements of the digital imaging system. The shape of the aperture can be but is not limited to circular, rectangular, elliptical, or triangular. The size of the aperture is preferably determined by the size of the particle and by the wavelength of the frequency of sound from the transducer. The aperture preferably should be a minimum of three times the particle diameter or 3mm whichever is greater. In embodiments of the invention, the size of the aperture may be varied with a mechanical iris to provide a highly accurate position of the particle. The thickness of the mask, is that which is sufficient to mask the sound, and may be as little as 1 mm as long as the sound reflectivity coefficient of the mask is sufficient to reflect most of the sound energy. In
embodiments of the invention, it has been found that reflecting about greater than 80% or 90% or 95% provides a practical optimum. The maximum thickness of the mask has no theoretical limit and is practically limited by the number of sound wavelengths spacing between the transducer and reflector (i.e. the mask thickness may be equal to one wavelength if the spacing between transducer and reflector is two wavelengths leaving one wavelength above the aperture for inspection and weighing in free space. Multiple apertures may be placed in the mask to allow formation of parallel acoustic standing waves.
[00159]Apertures formed within the sound mask preferably a minimum spacing that prevents the acoustic standing waves from interacting with each other and to allow spacing sufficient such that optical and mechanical instruments are able to operate on the particles hovering within the individual acoustic standing waves. A minimum spacing between apertures is preferably equal to or greater to the aperture size. The mask may be mounted such that it can rotate or translate in an X-Y orthogonal manner to move the acoustic standing wave(s) to desired position above the transducer. Motorized mechanisms can be used to provide exact positioning of the acoustic standing wave(s) to present hovering particles before digital imaging systems for weighing and inspection, defect extraction, or the output mechanism. Multiple instruments may be positioned in a radial fashion, subject to instrument spacing requirements, such that the acoustic aperture rotates the acoustic standing wave(s) into positions in front of each instrument for processing.
[00160] One illustrative embodiment in which this may be accomplished is illustrated, for example, in Figure 7. In such embodiments, a single particle may be manipulated within each standing wave column, or multiple particles may be manipulated within one or each standing wave column as described.
[00161] Figure 7 illustrates an example embodiment of an apparatus 10 and method for moving and/or dispensing levitated particles comprises a moving (rotating or translating) capture window 112 dispensed above the levitation transducer 12. In embodiments of the invention, this capture window 112 comprises an "acoustic aperture" to localize the acoustic field to a diameter which is much smaller than that of the acoustic field produced by the transducer. In one aspect, the acoustic aperture comprises sound mask, which may be implemented as a rotatable plate 114 with a plurality of apertures 116 (preferably circular) formed therethrough. The plate 114 is configured and
suspended between the transducer 12 and the reflector 14, such that the apertures 116 are positioned over the transducer so that the sound is reflected by the plate 114 back to the transducer, except in the apertures 116, where sound energy passes through and hits the reflector 14 to form a plurality of standing waves 20. At least one particle 20 is stably levitated in each of the aperture 116 regions. The aperture size may be determined by the particle size to be manipulated; in embodiments of the invention, these apertures may range in size from about 10 to 30 mm in diameter. Levitated particles can be moved radially by moving the position the apertures 116. In
embodiments of the invention, the plate 114 (and corresponding apertures 116) may be rotated around a center of the transducer sound field by means of a drive motor 118 mounted upon a support member 120 and mechanically communicating with a gear system 122. In embodiments of the invention, the acoustic aperture system may be controlled by a general or specific purpose computer, CPU or processor 124.
[00162] While Figure 7 depicts the acoustic window as implemented with a rotatable disk, other configurations are possible and intended, for example the acoustic window could comprise a plate comprising a sound mask, which plate is translatable in an XY direction, in addition to or alternatively to being rotatable. Additionally, the plate comprising the sound mask could be offset from a center of transducer 12 such that rotation of the plate could be used to sequentially carry a particle or particles entrained in one of the acoustic standing waves 20 to a location where the particle can be dispensed, for example by further masking the standing wave 20, or simply by moving the plate sufficiently out of range of the sound energy generated by the transducer 12.
[00163] Figures 1 , 6 and 7 illustrate the apparatus in stylized schematic form. An implementation of the apparatus could include a housing or enclosed structure for mounting the various components. The reflector may include a fine adjustment mechanism (i.e. a threaded rod connecting the reflector to a horizontal brace structure within the housing). If supplied, the calibration microphone may include a mechanical means to position it. Other components which could be mounted to the housing may comprise the optical imaging lens, body and sensor; the defect extraction system; the transducer; the material transport system; and the output device(s). Other imaging systems may be supplied in mounted within the housing for inspection of particles or droplets.
[00164] In embodiments of the invention, within the housing may also be sensors for measuring temperature, humidity, and barometric atmospheric pressure within the housing. The location of the sensors would preferably be as close as possible to, but not interfering with, the acoustic sound wave. Outputs from one or more of these sensors could be used to control, via the computing system, or via a dedicated control system, elements of the levitation apparatus. For example, changes in temperature or pressure may be used to compensate the transducer drive levels to maintain calibrated acoustic sound pressure or to adjust the transducer and reflector spacing to maintain minimal phase differences in the acoustic standing wave. All electronic drive components for the input system, microphone, optical imaging, defect extraction, transducer, reflector adjustment, lateral transport, and sensors could be located outside the primary housing in a separate enclosure and may or may not be attached to the housing. The external electronic component enclosure may or may not include the computer control system as some embodiments may use a laptop computer and other embodiments may use an embedded host computer in the enclosure.
[00165] In embodiments of the invention, the apparatus has been described as controlled by a computing system 62 comprising a computer processor. The program environment in which one embodiment of the invention may be executed illustratively incorporates one or more general-purpose computers or special-purpose devices such hand-held computers. Details of such devices (e.g., processor, memory, data storage, input, and output devices) are well known and are omitted for the sake of clarity.
[00166] It should also be understood that the elements of controlling the apparatus and methods of the present invention may be implemented using a variety of technologies. For example, aspects of methods described herein may be implemented in software running on a computer system, and/or implemented in hardware utilizing one or more processors and logic (hardware and/or software) for performing operations of the method, application specific integrated circuits (ASICs), programmable logic devices such as field programmable gate arrays (FPGAs), and/or various combinations thereof.
[00167] Accordingly, computing system 62 may be used to control some, a portion, or all elements of the apparatus 10 which require or benefit from computer control. Thus in embodiments of the invention, one, two, three, or all of the dedicated computers 81 , 90, 104 and 124 may be dispensed with and more than one, or each element of the apparatus 10 controlled by a single computing system 62.
[00168] Whilst the examples herein have generally described the apparatus of the present invention in terms of levitating a single particle, the system and method is not so limited. Multiple particles can undergo one or more of the processes of levitation, weighing, characterization and dispensing. This can be accomplished, for example by levitating multiple particles or droplets into multiple nodes of a single standing wave, for example, as depicted schematically in Figure 4, wherein the particles can form a column within each capture node 18 of the standing wave 20 above transducer 12. In such embodiments, particles can be moved up and down the column by manipulating sound pressure, for example by decreasing sound pressure to move particles downward towards the transducer, and increasing sound pressure to capture particles again within a capture node. Effectively, a pipeline of particles can be manipulated in this manner, and one or more of the steps comprising levitation, weighing characterizing and dispensing may be performed sequentially or simultaneously.
[00169] Examples: The following examples illustrate the invention without limiting its scope.
EXPERIMENTAL
[00170] By imaging with an optical system (see e.g. the camera in Fig. 5, the levitation heights tabulated in Table 1 were determined:
Example 1
Table 1 . Particle levitation height versus weight
[00171] These experimental values are represented in Fig. 3 in a logarithmic scale, where also the resulting exponential function is represented. Particle levitation height is
shown on the horizontal axis in mm (origin is arbitrary), and weight is shown on the vertical axis.
[00172] Standard statistical methods were used to correlate the measured data with actual values. In this example, a power law was used and resulted in a fit parameter that is very nearly 1 .0, indicating an excellent fit. The particular statistical analysis employed was a two parameter to three data points function, which means that there is one more degree of freedom in the model. Consequently it would be possible for the curve fit to not pass perfectly through all three points. A parabolic fit could also be utilized, which would be expected to yield a fit parameter of exactly 1 .0 because there would be three degrees of freedom in the data and three degrees of freedom in the model. In Table 1 , column 1 is the diameter of the particles, column 2 is the levitation height in the positive pressure node, column 3 is the known weight of the particle, column 4 is the calculated weight (referred to as Mass Trend) of the particle based on mathematical curve fitting, column 5 is the absolute error percentage between the known weight and the calculated weight, and column 6 is the calculated weight in milligrams for reference. The average error for this measurement is 5.3%. Particles used to obtain the data of Table 1 were 100u particles (Dri-Cal DC-100); 50u particles (ChromoSpheres-T BK050T); and 20u particles (Dri-Cal DC-20); all from Thermo Scientific. While not shown in the table, actual drug particles (comprising ibuprofen) of different sizes, and of higher density than the test particles were successfully levitated as well.
Example 2
[00173] A Power Amplifier board from Power Amp Design, and a 120V Power supply was used to drive au ultrasonic transducer made by STEM, Inc. cleanly to a full 80 Watts of power. Expanded Styrofoam beads of 3mm diameter and weighing approximately 50 milligrams each were levitated. I can levitate multiple beads in a vertical stack. The number of beads is dependent on the number of wavelengths in the space between the transducer and the reflector. Multiple (at least four 4) beads were levitated
simultaneously, that is each in a different vertical node.
Example 3
[00174] In this example, an "acoustic aperture" was made to localize the acoustic field to a relatively small diameter. An acoustically opaque plate, with a circular aperture about
twenty five mm in diameter, was suspended between the transducer and the reflector. The circular aperture was positioned over the transducer so that the sound was reflected back to the transducer except the where sound passed through the circular aperture and hit the reflector to form the standing wave. Styrofoam beads (as test particles) were introduced into the circular aperture and were stably levitated, as determined by the absence of visible movement to the naked eye. The aperture size may be determined by the particle size to be manipulated. In embodiments of the invention a minimum aperture size is 3x the diameter of the particle, for example a 3 mm aperture for a 1 mm particle diameter. The bead's position can be altered by moving the position of the aperture around the transducer sound field. The purpose of this feature is to provide positioning of the particle within the apparatus for multiple operations while the particle is held in a relatively constant vertical position by the acoustic standing wave
Example 4
[00175] In this example, an embodiment of the apparatus was made wherein the reflector contains a plurality of small apertures designed and configured for dropping beads into the sound field for levitation. Expanded polystyrene test beads were dropped (manually) beads through one of the apertures in the reflector and were captured in an uppermost capture node of the levitation field in ten out of ten attempts. This experiment demonstrates that particles can be inputted into the levitation field by dropping them through the reflector. The size of the hole and the drop distance to the capture field are important. The size of the hole should be minimized to reduce impact on the acoustic standing wave because a hole allows some portion of the sound pressure to escape rather than be reflected back to the transducer. The drop distance is important because the acceleration of the particle due to gravity must be offset by the sound pressure to decelerate the particle to zero velocity and be captured in the capture node.
[00176] While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation. Thus, the breadth and scope of a preferred embodiment should not be limited by any of the above- described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
Claims
1 . A method of determining a property of a particle of material, comprising: providing a levitation field comprising an acoustic standing wave; introducing said particle of material into the levitation field wherein the material is allowed to position itself at an acoustic pressure node of the standing wave; determining at least one of a position of the material and an orientation of the material the in the acoustic pressure node; and using the information to determine a property of the material.
2. The method of claim 1 wherein the material is a solid particle or a liquid
droplet.
3. The method of claim 1 wherein the property comprises weight.
4. The method of claim 1 wherein the property comprises a characteristic.
5. The method according to claim 1 wherein said orientation is determined by subjecting the material to a transverse acoustic wave.
6. The method according to claim 5, further comprising determining a shape of the material by subjecting the material to the transverse acoustic wave.
7. The method according to any of claims 1 to 6, wherein the material is a result of liquid material comprising a solution or dispersion, including a suspension of a solid material in a solvent or solvent mixture or an emulsion of a liquid material in a solvent or solvent mixture that is not miscible with the solvent.
8. The method according to claim 7 wherein the material is solid and comprises pulverous, crystalline, amorphous, a granule, an agglomerate of particles, a mixture of solid states, micelle material, liposome material, a viral material, a cell component, cell material or entrapment material.
9. The method according to any of claims 1 to 6 where the material comprises a drug, a drug and excipient combination, an excipient, an intermediate for the synthesis of a drug, a cell component or a cell, a food product, a
nutraceutical, or a radioactive material.
10. The method according to any of claims 1 to 9, wherein position is determined by an optical system.
1 1 . The method according to any of claims 1 to 10, wherein multiple particles are introduced into multiple nodes of the same standing wave simultaneously or sequentially and the determination of the weight of each particle takes place in parallel.
12. A method of dispensing a material in the form of a solid particle or a liquid droplet or mixture, comprising: providing a levitation field comprising an acoustic standing wave; introducing said material into said levitation field, so that it is positioned and kept in position by an acoustic pressure node of the standing wave, determining information on one or more features selected from position, shape, weight and orientation of the material; and using the obtained feature to dispense the material into a destination.
13. The method according to claim 12, wherein the weight is determined by sensing the position of the material within the acoustic standing wave relative to a datum.
14. The method according to any of claims 12 or 13, wherein the destination is selected based on the information one or more of the features selected from position, shape, weight, form, size and orientation of the material.
15. The method according to claim 14, comprising dispensing more than one material particle or droplet to the same destination and thus accumulating the material at that destination.
16. The method according to any of claims 12 to 15 wherein the material comprises one or more drugs, a drug formulation comprising one or more drugs with one or more excipients, or a placebo.
17. The method according to any of claims 12 to 16, wherein the dispensing of the material comprises shifting the position of said material so that it enters a device or container as a final destination.
18. The method according to any of claims 9 to 17, wherein the shifting
comprises applying one or more of; a transverse or superimposed acoustic wave, an electrical field, a gas or fluid stream, or an acoustic aperture.
19. The method according to any of claims 9 to 17, comprising shifting the
material to the destination by weakening or removing the acoustic levitation field, allowing a particle or droplet of the material to fall into a destination positioned below the levitation field.
20. The method according to any of claims 12 to 17, wherein the position of the material within the acoustic standing wave is determined by an optical system or by an audio system, or both.
21 . The method according to any of claims 12 to 20, comprising providing the material with an electric charge.
22. The method according to any of claims 1 to 21 , comprising determining the weight of the material by calibration with particles or droplets of known weight.
23. A system for assessing properties of a particle or droplet, the system
comprising an acoustic transducer pair, a particle singulation system, an optical position sensing device, and a computer processor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2015/094697 | 2015-11-16 | ||
PCT/CN2015/094697 WO2017084012A1 (en) | 2015-11-16 | 2015-11-16 | Acoustic material weighing and manipulation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017085613A1 true WO2017085613A1 (en) | 2017-05-26 |
WO2017085613A4 WO2017085613A4 (en) | 2017-07-20 |
Family
ID=57392014
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/094697 WO2017084012A1 (en) | 2015-11-16 | 2015-11-16 | Acoustic material weighing and manipulation |
PCT/IB2016/056846 WO2017085613A1 (en) | 2015-11-16 | 2016-11-14 | Weighing and characterizing materials by acoustic levitation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/094697 WO2017084012A1 (en) | 2015-11-16 | 2015-11-16 | Acoustic material weighing and manipulation |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2017084012A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020018967A1 (en) * | 2018-07-20 | 2020-01-23 | Koval Richard David | Method and apparatus for determining a mass of a droplet from sample data collected from a liquid droplet dispensation system |
EP3978144A4 (en) * | 2019-05-31 | 2022-08-03 | DGSHAPE Corporation | Droplet deposition device |
US20230041135A1 (en) * | 2020-01-27 | 2023-02-09 | The Administrators Of The Tulane Educational Fund | Apparatus, Systems And Methods For In Vitro Screening Of Complex Biological Fluids |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107591066A (en) * | 2017-10-24 | 2018-01-16 | 西北工业大学 | A kind of controllable acoustic levitation experimental provision of more physical environments |
DE102017129763A1 (en) * | 2017-12-13 | 2019-06-13 | Universität Hamburg | Method and device for coating a single particle |
CN109269630B (en) * | 2018-08-30 | 2021-07-02 | 哈尔滨工业大学(威海) | Underwater ultrasonic suspension field measuring device and using method |
CN109695437B (en) * | 2018-12-27 | 2021-05-21 | 西南石油大学 | Gas well ultrasonic suspension liquid drainage gas production system and implementation method |
WO2020232348A1 (en) * | 2019-05-15 | 2020-11-19 | The Regents Of The University Of California | Omnidirectional spiral surface acoustic wave generation |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4420977A (en) * | 1982-03-15 | 1983-12-20 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Acoustic rotation control |
US5036944A (en) * | 1986-03-24 | 1991-08-06 | Intersonics Incorporated | Method and apparatus for acoustic levitation |
WO2000019176A1 (en) | 1998-09-25 | 2000-04-06 | Panametrics, Inc. | Ultrasonic measurement system with molecular weight determination |
US6109098A (en) | 1998-06-30 | 2000-08-29 | Doukhin Dispersion Technology, Inc. | Particle size distribution and zeta potential using acoustic and electroacoustic spectroscopy |
US7080556B2 (en) | 2002-06-14 | 2006-07-25 | National Research Council Of Canada | Ultrasonic apparatus and methods for the monitoring of melting, mixing and chemical reaction processes |
US20120197005A1 (en) | 2011-01-31 | 2012-08-02 | Uchicago Argonne, Llc | Containerless synthesis of amorphous and nanophase organic materials |
WO2014081084A1 (en) | 2012-11-20 | 2014-05-30 | 지에스칼텍스(주) | Recombinant microorganism with improved butanol productivity and method for producing butanol by using same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5890580A (en) * | 1993-07-12 | 1999-04-06 | Kaijo Corporation | Object levitating apparatus, object transporting apparatus, and object levitating bearing along with an object levitating process and object transporting process |
JP2005239391A (en) * | 2004-02-27 | 2005-09-08 | Toyota Industries Corp | Object levitation device and object levitation carrying device |
CN202935948U (en) * | 2012-08-15 | 2013-05-15 | 吉林大学 | Ultrasonic wave and air floatation mixed non-contact automatic conveying device |
CN104085691A (en) * | 2014-07-30 | 2014-10-08 | 华东理工大学 | Ultrasonic suspension conveying device |
-
2015
- 2015-11-16 WO PCT/CN2015/094697 patent/WO2017084012A1/en active Application Filing
-
2016
- 2016-11-14 WO PCT/IB2016/056846 patent/WO2017085613A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4420977A (en) * | 1982-03-15 | 1983-12-20 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Acoustic rotation control |
US5036944A (en) * | 1986-03-24 | 1991-08-06 | Intersonics Incorporated | Method and apparatus for acoustic levitation |
US6109098A (en) | 1998-06-30 | 2000-08-29 | Doukhin Dispersion Technology, Inc. | Particle size distribution and zeta potential using acoustic and electroacoustic spectroscopy |
WO2000019176A1 (en) | 1998-09-25 | 2000-04-06 | Panametrics, Inc. | Ultrasonic measurement system with molecular weight determination |
US7080556B2 (en) | 2002-06-14 | 2006-07-25 | National Research Council Of Canada | Ultrasonic apparatus and methods for the monitoring of melting, mixing and chemical reaction processes |
US20120197005A1 (en) | 2011-01-31 | 2012-08-02 | Uchicago Argonne, Llc | Containerless synthesis of amorphous and nanophase organic materials |
WO2014081084A1 (en) | 2012-11-20 | 2014-05-30 | 지에스칼텍스(주) | Recombinant microorganism with improved butanol productivity and method for producing butanol by using same |
Non-Patent Citations (2)
Title |
---|
KAVOURAS A ET AL: "Ultrasonic levitation for the examination of gas/solid reactions", REVIEW OF SCIENTIFIC INSTRUMENTS, AIP, MELVILLE, NY, US, vol. 74, no. 10, 1 October 2003 (2003-10-01), pages 4468 - 4473, XP012040464, ISSN: 0034-6748, DOI: 10.1063/1.1606532 * |
LEITERER J ET AL: "Structure analysis using acoustically levitated droplets", ANALYTICAL AND BIOANALYTICAL CHEMISTRY, SPRINGER, BERLIN, DE, vol. 391, no. 4, 30 March 2008 (2008-03-30), pages 1221 - 1228, XP019621388, ISSN: 1618-2650 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020018967A1 (en) * | 2018-07-20 | 2020-01-23 | Koval Richard David | Method and apparatus for determining a mass of a droplet from sample data collected from a liquid droplet dispensation system |
US11255715B2 (en) | 2018-07-20 | 2022-02-22 | Brighton technologies, LLC | Method and apparatus for determining a mass of a droplet from sample data collected from a liquid droplet dispensation system |
EP3978144A4 (en) * | 2019-05-31 | 2022-08-03 | DGSHAPE Corporation | Droplet deposition device |
US11478812B2 (en) | 2019-05-31 | 2022-10-25 | DGSHAPE Corporation | Droplet deposition apparatus |
US20230041135A1 (en) * | 2020-01-27 | 2023-02-09 | The Administrators Of The Tulane Educational Fund | Apparatus, Systems And Methods For In Vitro Screening Of Complex Biological Fluids |
EP4096848A4 (en) * | 2020-01-27 | 2024-02-28 | The Administrators Of The Tulane Educational Fund | Apparatus, systems and methods for in vitro screening of complex biological fluids |
Also Published As
Publication number | Publication date |
---|---|
WO2017084012A1 (en) | 2017-05-26 |
WO2017085613A4 (en) | 2017-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017085613A1 (en) | Weighing and characterizing materials by acoustic levitation | |
Tran et al. | Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs | |
Jarvis et al. | Nanocrystals: A perspective on translational research and clinical studies | |
Patil et al. | Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC) | |
KR20200015828A (en) | Inhalable pharmaceutical compositions | |
Weng et al. | Cocrystal engineering of itraconazole with suberic acid via rotary evaporation and spray drying | |
Edwards | Applications of capsule dosing techniques for use in dry powder inhalers | |
US11324699B2 (en) | Lipid multiparticulate formulations | |
Mirza et al. | 3D printing in pharmaceuticals: Regulatory perspective | |
Hadiwinoto et al. | Integrated continuous plug-flow crystallization and spray drying of pharmaceuticals for dry powder inhalation | |
Dereymaker et al. | Controlling the release of indomethacin from glass solutions layered with a rate controlling membrane using fluid-bed processing. Part 1: surface and cross-sectional chemical analysis | |
Suzuki et al. | Amorphous solid dispersion of cyclosporine A prepared with fine droplet drying process: Physicochemical and pharmacokinetic characterization | |
Loh et al. | Do lipid-based nanoparticles hold promise for advancing the clinical translation of anticancer alkaloids? | |
Khuroo et al. | Very-rapidly dissolving printlets of isoniazid manufactured by SLS 3D printing: in vitro and in vivo characterization | |
Zakowiecki et al. | The improvement of the dissolution rate of ziprasidone free base from solid oral formulations | |
Wu et al. | Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants | |
Zhang et al. | Enhanced oral bioavailability of salmeterol by loaded PLGA microspheres: preparation, in vitro, and in vivo evaluation | |
O’Donnell et al. | Optimizing the formulation of poorly water-soluble drugs | |
Shi et al. | Progress in the study of drug nanocrystals | |
WO2022125882A1 (en) | Oral capsule cannabinoid formulations | |
Sahoo et al. | Preparation, characterization and dissolution behavior of artemisinin microparticles | |
Sapalidis et al. | Inhaled immunotherapy administration for lung cancer; efficient? Certainly possible | |
Szabó et al. | The role of solid state characterization in predicting stability of solid dosage forms | |
Ma et al. | Treatment of idiopathic pulmonary fibrosis by inhaled silybin dry powder prepared via the nanosuspension spray drying technology | |
Budiman et al. | Amorphous Solid Dispersion as Drug Delivery Vehicles in Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16801052 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16801052 Country of ref document: EP Kind code of ref document: A1 |